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ABSTRACT 
 
 
 CD9, a member of the tetraspanin family, is highly expressed on platelets 
(50,000-80,000 copies per platelet). Tetraspanins have been implicated in 
modulation of integrin function, and it is hypothesized that CD9 will modulate 
GPIIb-IIIa, the major platelet integrin. 
 
 The association between CD9 and GPIIb-IIIa was analyzed using 
immunoprecipitations and confocal microscopy. These two proteins were found 
to associate with each other, particularly at areas of platelet-platelet contact and 
at the periphery. Confocal analysis revealed CD9 localization was most intense 
at platelet-platelet contact, as well as in platelet filopodia and lamellipodia, but 
there is a lack of CD9 at areas of platelet-matrix contact. Co-localization with F-
actin decreased as platelets progressed through the stages of spreading. 
 
 In order to analyze CD9 contributions to platelet function, a Fab fragment 
was generated from mAb7, an antibody which binds with high affinity to the large 
extracellular loop of CD9. Fab fragments were used to avoid complications of 
bound antibody crosslinking CD9 with the platelet FcγRII receptor. Confocal 
analysis of platelet spreading indicated that CD9 perturbation by mFab7 resulted 
in increased platelet spreading on a variety of matrices, although platelet 
adhesion was unaffected on all matrices except fibrin. Platelet-platelet 
interactions, including aggregation and disaggregation, were studied using light 
transmission aggregometry. CD9 perturbation increased the extent of platelet 
aggregation in response to threshold levels of agonist, with diminished effect with 
more potent agonists such as TRAP (Thrombin Receptor Agonist Peptide). CD9 
perturbation also diminished, but did not completely inhibit, platelet 
disaggregation induced by eptifibatide. Interestingly, CD9 perturbation did not 
alter platelet-mediated clot retraction of platelets in PRP (Platelet rich plasma). In 
response to CD9 alteration by mFab7, both increased fibrinogen binding and 
platelet activation (as evidenced by CD63 and P-selectin expression) were 
elicited in the presence of threshold ADP levels. Both responses were dependent 
on presence of low-level agonist, as CD9 perturbation in the absence of agonist 
yielded no effect. 
 
 Cytoskeletal isolation revealed that CD9 perturbation results in increased 
incorporation of actin and other cytoskeletal molecules into the platelet core 
cytoskeleton. Immunoprecipitations results showed increased CD63 
incorporation into the tetraspanin web, although the level of CD9 coprecipitation 
with GPIIb-IIIa was unaffected. A preliminary analysis of tyrosine 
phosphorylation, particularly Akt, did not reveal alterations on tyrosine 
phosphorylation of signaling molecules. 
 
 These results suggest that CD9 functions as a scaffold, organizing 
molecules into specific domains on the platelet surface. It appears to function as 
vi 
a ―gatekeeper‖ for GPIIb-IIIa activation, particularly modulating activation and 
aggregate stability at low levels of agonist. 
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CHAPTER 1   INTRODUCTION 
  
 
1.1   Overview 
 
Platelets are anucleate, disc-shaped cell fragments generated from 
megakaryocytes. They circulate through the vasculature and play a dual role in 
that they are critical for regulating hemostasis and wound healing (constituting a 
primary defense against bleeding) and thrombosis (which can lead to thrombotic 
disorders under pathological conditions). Platelets express a wide array of 
adhesion receptors that mediate adhesion, spreading, and cell-cell interactions. 
Tetraspanins are one family of proteins that modulate cell adhesion events in 
concert with integrins. Platelets express several tetraspanins—most prominently 
CD9—at 50,000-80,000 copies per platelet.  
 
Tetraspanins constitute a unique class of integral membrane-spanning 
proteins. Four transmembrane domains, intracellular carboxy and amino termini, 
two extracellular loops, and unique motifs in the large extracellular loop 
characterize this family of proteins. Tetraspanins have been implicated in 
regulation of platelet integrin function, such as platelet adhesion, activation, and 
aggregation, yet the exact role of CD9 in human platelets has remained unclear. 
Based upon data in other cell model systems, it is hypothesized that CD9 may 
regulate platelet adhesive functions by regulating integrin activation and post- 
receptor occupancy events, such as thrombus stability. 
 
 
1.2   Purpose of the Study 
 
 The purpose of this study is to determine the role of CD9 in human 
platelets. For the first time, the functional activity of CD9 in platelets will be 
defined by using a well-characterized anti-CD9 Fab fragment generated from an 
antibody (mAb7) that has been shown in other studies to modulate cell adhesive 
events. These data are critical for understanding which aspects of platelet 
function tetraspanins most influence and how tetraspanins, specifically CD9, may 
regulate platelet response to vascular injury. It is also hypothesized that CD9 
function likely occurs on the platelet surface—such as adhesive functions or 
interaction with the integrin GPIIb-IIIa—mediated through its extracellular loops. 
This is because specific motifs in its cytoplasmic domains known to interact with 
platelet signaling molecules or adaptor proteins have not been identified. Thus, 
CD9 through its extracellular loop regions may function at threshold levels of 
activation, with a role in regulating the extent of integrin activation. 
 
Through understanding the function of CD9, the influences of platelet 
pathophysiological responses can be further appreciated. These findings may 
lead to advances in wound healing, hemostasis and thrombosis, and vascular 
2 
bed diseases such as acute coronary syndromes by targeting CD9 and its 
function for pharmacological intervention. 
 
 
1.3   Aims and Research Questions 
 
 
1.3.1   Specific Aim 1 
  
 Determine the localization and protein partners of CD9 in human platelets. 
Flow cytometry will be performed to analyze CD9 expression in resting and 
activated platelets, which will shed insight if CD9 is primarily important in platelet 
activation or activated platelets, or if it primarily regulates other proteins during 
platelet events. Flow cytometry will also reveal relative surface expression of 
other members of the tetraspanin web in resting and activated platelets. 
 
 Immunoprecipitation and confocal microscopy will be used to determine 
the association and localization of CD9 and GPIIb-IIIa, the primary platelet 
integrin. It is anticipated that CD9 might exert its effect through regulating the 
extent of GPIIb-IIIa activation. These results will yield insight into the effect of 
platelet activation and integrin ligand binding on the CD9-GPIIb-IIIa association 
by platelets spread on substrate and in suspension. Experiments with platelets 
expressing a mutant GPIIb-IIIa will provide preliminary insight into possible areas 
of GPIIb-IIIa critical to its association with CD9. 
 
 Confocal microscopy will also be used to analyze the localization of CD9 
into platelet spreading structures such as filopodia, lamellipodia, and platelet-
platelet contact sites to initially determine if CD9 is involved in platelet adhesive 
events. Co-localization with F-actin will yield insight into CD9’s linkage with the 
cytoskeleton, although this could occur directly or indirectly through other 
members of the tetraspanin web. 
 
 
1.3.2   Specific Aim 2 
 
 Determine platelet functions affected by CD9 perturbation. The effect of 
CD9 on platelet events will be determined by creating a Fab fragment which 
binds to the extracellular region of CD9. The full-length antibody has been shown 
to have a functional effect in smooth muscle cells and Chinese hamster ovary 
cells. A Fab fragment is used here to ensure that results are due to CD9 ligation 
without involvement of the receptor FcγRII. 
 
 Major platelet functions involved in this study include platelet aggregation 
and disaggregation, platelet adhesion and spreading on four substrate 
matrices—all of which are ligands for GPIIb-IIIa, ligand binding and platelet 
activation (via flow cytometry), and platelet-mediated clot retraction. These 
3 
events are mediated by GPIIb-IIIa, and it is anticipated that CD9, by regulating 
this integrin, will alter these events. 
 
 Aggregation and disaggregation, ligand binding, and platelet activation will 
be analyzed using low concentrations of platelet agonists. It is anticipated that 
CD9 will function as a gatekeeper for integrin activation, and that its impact will 
be most pronounced at threshold levels of platelet activation. Stronger levels of 
agonist would be expected to overwhelmingly activate the integrin, regardless of 
CD9 signaling. 
 
 
1.3.3   Specific Aim 3 
 
 Determine mechanisms involved in the contribution of CD9 to platelet 
function. This includes examination of the tetraspanin web, incorporation of 
cytoskeletal proteins into the core cytoskeleton, phosphorylation of key signaling 
molecules, and the effect of CD9 perturbation on each. 
 
CD9 may function as a membrane protein scaffold, and may be critical in 
recruiting cell surface molecules and organizing signaling complexes in the 
tetraspanin web. In this role, CD9 may function to keep proteins in contact with or 
away from GPIIb-IIIa or to maintain a desirable (active or inactive) conformation 
of GPIIb-IIIa. Flow cytometry will analyze the impact of CD9 perturbation on 
association of CD9, GPIIb-IIIa, and CD63 in resting and activated platelets. 
Platelet core cytoskeletons will be isolated and analyzed to determine the role of 
CD9 on the incorporation of cytoskeletal proteins. Platelet signaling molecules 
will also be evaluated, primarily phosphorylation of Akt. Research in our lab has 
shown the Akt pathway to be the primary CD9 signaling pathway (Kotha 2008). 
However, total tyrosine phosphorylation will also be analyzed to examine a 
possible involvement of another pathway.  
 
It is anticipated that the linkage of CD9 to the cytoskeleton or signaling 
molecules is indirect, through GPIIb-IIIa, due to the short intracellular regions of 
CD9, although a novel CD9 binding partner may be discovered. Since CD9 is 
likely involved in mediating activation of GPIIb-IIIa, its cytosolic partners could 
also be altered. 
  
 
1.4   Significance 
 
 Genetic research shows a biological significance for tetraspanins in 
mammalian systems. Inactivation of the tetraspanin TALLA-1 causes X-linked 
mental retardation (Zemni 2000); CD9 and CD81 knock-out mice have reduced 
fertility, with double knock-out mice being completely infertile (Kaji 2000, LaNaour 
2000, Miyado 2000, Rubinstein 2006); and CD37 knock-out mice have reduced 
4 
immune response. In the platelet system, CD151 or TSSC-6 knock-out mice 
have impaired integrin outside-in signaling (Goschnick 2006, Lau 2004). 
 
 Currently available studies of CD9 functions in platelets have yielded 
limited information. At present, there have been no published studies showing 
defects or abnormalities in platelet function in the CD9 knock-out mice; however, 
there is no information regarding expression levels of (and possible 
compensation by) other tetraspanins or integrins. Use of anti-CD9 antibodies 
have consistently activated signaling mechanisms through the receptor FcγRII, 
making interpretation of results difficult. In this study, Fab fragments will be used 
in place of antibodies; thus, CD9 ligation can still be achieved without the 
involvement of the FcγRII. 
 
 The results of this project will lead to better understanding of the basic 
biology of CD9 and its role in platelet function. This will add to the knowledge of 
platelet function that could lead to the development of pharmacological agents 
that target CD9 and arrest thrombosis. 
 
 These results will also lead to a broader understanding of cell adhesive 
function and better define a family of molecules that regulate integrins, key 
receptors in cell adhesion, differentiation, and proliferation of cells. The functional 
role of the CD9-GPIIb-IIIa interaction is, at present, poorly defined.  The ability of 
tetraspanins to modulate integrin conformation, as well as membrane complexes, 
ligand binding, and integrin-associated cell signaling pathways, will be more 
clearly defined, and our understanding of communication through platelet-platelet 
and platelet-matrix interactions will be advanced. 
5 
CHAPTER 2 REVIEW OF LITERATURE 
 
 
2.1   Platelets 
 
 
2.1.1   Platelet Formation and Function 
 
 Platelets are small cell fragments released from megakaryocytes, 
composed of a membrane, cytoplasm, granules, and organelles. Approximately 
1011 platelets are produced in the human body on a daily basis; once released 
from the bone marrow megakaryocytes, they circulate in the blood for seven to 
ten days (Harker 1969). Their function is to maintain vascular integrity by 
regulating hemostasis and thrombosis. 
 
 Megakaryocytes are derived from hematopoietic stem cells (HSCs), which 
evolve from the multipotent haemangioblast, the precursor for all blood and blood 
vessel cells. The HSC yields the early Common Myeloid Progenitor (CMP), which 
is cloned as the (Granulocyte, Erythrocyte, Megakaryocyte and Monocyte) 
Colony-Forming Unit (CFU-GEMM). The CMP differentiates into the 
Megakaryocyte-Erythroid Progenitor (MEP), which yields both the erythroid and 
megakaryocytic lineages, controlled by GATA-1 (which regulates granulocyte 
and monocyte precursors). Cytokines and chemokines, in response to 
environmental factors, allow differentiation of MEP into the highly proliferative 
BFU-MK (Megakaryocyte Burst-Forming Unit) or the more mature CFU-MK 
(megakaryocyte colony-forming unit). These cells progress into megakaryoblasts, 
which are incapable of cell division but able to replicate DNA (Deutsch 2006). 
This yields the immature, polyploid (up to 128 N) megakaryocyte (Tomer 1988), 
containing elevated RNA levels, prominent ribosomes and rough endoplasmic 
reticulum, alpha and dense granules, and a primitive demarcation membrane. 
The maturing megakaryocyte develops a horseshoe-shaped nucleus and an 
expanded cytoplasm and amplifies platelet organelles and the demarcation 
membrane, which is continuous with the plasma membrane (Breton-Gorius 
1976). The cell surface expresses GPIIb-IIIa (IIb3), GPIX, and GPIb, and the 
granules contain von Willebrand factor (vWF), platelet factor 4, β-
thromboglobulin, fibrinogen, coagulation factor VIII, and factor V (Breton-Gorius 
1976). Megakaryocytes occur in about one in 2000 nucleated bone marrow cells, 
although this number may increase ten-fold in response to thrombocytopenia 
(Branehog 1975). 
 
 The megakaryocyte can extend long proplatelet projections; the 
demarcation membrane serves primarily as a membrane reservoir for proplatelet 
formation.  These are filled with the proper specific organelles and granule 
contents, which migrate from the cell body to the proplatelet ends, to give rise to 
new circulating platelets (Italiano 1999, Italiano 2003). A single megakaryocyte 
may give rise to 2000-5000 new platelets (Long 1988). Two models suggest how 
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platelets arise: platelets may arise and bud off the tip of proplatelet (Choi 1995, 
Patel 2005), or there may be preformed territories with internal membranes that 
are released by fragmenting from the membrane ( Mori 1993, Zucker-Franklin 
1984). 
 
 Resting platelets circulate as small discs, approximately 0.5 x 3.0 μm in 
humans. An internal microtubule beneath the plasma membrane, composed of 
13 stacks of tubulin subunits arranged head-to-tail in protofilaments, maintains 
the disc shape (Lecine 2000). It remains unclear whether the microtubule coil has 
any other function, as well as any advantage of a disc-shape (Hartwig 2006). 
 
 An internal actin filament cytoskeleton maintains platelet integrity. The two 
main components of the actin filament cytoskeleton are the membrane skeleton 
and the cytoplasmic actin scaffold. 
 
 Upon platelet activation, the microtubule reorganizes into multiple short 
microtubules that run from the platelet center toward outward protrusions, as well 
as a forming a compressed coil in the center of a spread platelet. Microtubule 
kinetics is controlled by dynein, a minus-end-directed motor, and kinesins, which 
are mainly plus-end-directed motors (Hartwig 2006). 
 
 
2.1.2   Platelet Physiology 
 
 2.1.2.1   Activation by Agonists. Platelets express a number of agonist 
receptors: GPVI (collagen) (Clemetson 2001), PAR-1 and PAR-4 (thrombin) 
(Coughlin 2005), P2Y1 and P2Y12 (ADP) (Gachet 2006), and receptors for 
thromboxane A2 (Thomas 1998) and epinephrine (Pozgajova 2006). A summary 
of platelet agonists can be found in Table 2.1. 
 
 Platelet agonists can be found in increased concentrations at sites of 
vascular injury. They lead to platelet activation, causing shape change, integrin 
activation via inside-out signaling, and granule secretion (see Table 2.2).  
 
 2.1.2.2   Adhesion and Spreading. Immediately upon vascular injury, 
platelets tether to the exposed subendothelium and become activated by the 
agonists present at the site of injury (collagen and thrombin). Once activated, 
platelets become firmly adherent and will release their storage granules, which 
contain ADP and other substances (see Table 2.2). This in turn promotes 
additional platelet recruitment and platelet aggregation (Denis 2007) (see Fig 2.1 
and Fig 2.2). 
 
 Initial platelet tethering is mainly carried out by the GPIb-IX-IV complex 
binding to exposed von Willebrand factor (vWF) (see Fig 2.2), which undergoes a 
conformational change when bound to the matrix or exposed to high shear 
conditions (Bergmeier 2000, Berndt 2001, Ruggeri 2003). The interaction 
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Table 2.1 Comparison of Platelet Agonists 
 
 
Agonist 
 
Receptor 
 
G 
Protein 
 
Signaling 
Molecules 
 
 
Effect 
 
Importance 
 
Medical 
Targets 
ADP P2Y1 Gq PLC 
RhoA, Rac, 
Src kinase, 
PKC 
Weak, 
transient 
activation 
of GPIIb-
IIIa 
 
Shape change, 
initiation of 
aggregation 
 
 P2Y12 Gi2 Inhibit 
adenylyl 
cyclase 
and 
cytosolic 
cAMP; 
activate 
PI3K, 
Akt/PKB, 
Rap1b, src 
family 
kinases 
 
GPIIb-IIIa 
activation, 
dense 
granule 
release 
Sustained 
aggregation 
response, 
leading to 
thrombus 
growth and 
stabilization 
Ticlopidine 
Clopidigrel 
Thrombin PAR1 Gq, 
G12/13, 
Gi 
PLC, IP3, 
DAG, PKC, 
Rho/Rho 
kinase, 
inhibition of 
adenylyl 
cyclase 
Strong 
activation 
of GPIIb-
IIIa in 
response 
to low 
thrombin 
levels 
 
Cytoskeletal 
rearrange-
ment, shape 
change, 
degranulation, 
adhesion 
 
 PAR4 Gq, 
G12/13 
PLC, IP3, 
DAG, PKC, 
Rho/Rho 
kinase, 
Strong 
activation 
of 
GPIIb-IIIa  
in 
response 
to high 
thrombin 
levels 
 
Cytoskeletal 
rearrangement, 
shape change, 
degranulation, 
adhesion 
 
Collagen  ---- Syk, SLP-
76, PLC 
Activation 
of GPIIb-
IIIa 
Outside-in 
platelet 
activation 
 
 
 
 
 
(continued) 
GPVI, 
GPIV 
---- Src, Fyn, 
Lyn, Syk, 
PI3K 
Activation 
of GPIIb-
IIIa 
 
Calcium 
release 
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Table 2.1 (continued) 
 
 
Agonist 
 
Receptor 
 
G 
Protein 
 
 
Signaling 
Molecules 
 
Effect 
 
Importance 
 
Medical 
Targets 
Epin- 
ephrine 
2-
adrenergic 
receptors 
---- IP3, DAG, 
PKC, PLC 
Activation 
of GPIIb-
IIIa 
Granule 
secretion, 
aggregation 
Aspirin, 
NSAIDS, 
others 
Source:  
Bennett JS. Structure and function of the platelet integrin aIIbb3. J Clin Invest. 
2005; 115: 3363-3369.  
 
Gachet C. Regulation of platelet functions by P2 receptors. Ann Rev Pharmacol 
Toxicol. 2006; 26: 277-300. 
 
 Kahner BN, Shankar H, Murugappan S, Prasad GL, Kunapuli SP. Nucleotide 
receptor signaling in platelets. J Thromb Haemost. 2006; 4 (11): 2317-
2326. 
 
Offermans S. Activation of platelet function through G protein-coupled receptors. 
Circ Research. 2006; 99: 1293-1304. 
 
Samaha FF, Kahn ML. Novel platelet and vascular roles for immunoreceptor 
signaling. Arterioscler Thromb Vasc Biol. 2006; 26: 2588-2593. 
 
Voss B, McLaughlin JN, Holinstat M, Zent R, Hamm HE. PAR1, but not PAR4, 
activates human platelets through a Gi/o/phosphoinosite-3 kinase 
signaling axis. Molec Pharmacol. 2007; 71 (5): 1399-1406. 
 
Watson SP, Auger JM, McCarty OJT, Pearce AC. GPVI and integrin αIIbβ3 
signaling in platelets. J Thromb Haemost. 2005; 3 (8): 1752-1762. 
9 
Table 2.2 Platelet Granules 
 
 
Granule 
 
Alpha Granules 
 
 
Dense Granules 
 
Lysosomes 
# per platelet 80 7 2-4 
 
Contents Growth factors, 
coagulation proteins, 
adhesion molecules, 
cytokines, cell-
activating agents, 
angiogenic factors, 
platelet-specific 
molecules 
(coagulation factor V, 
thrombospondin, P-
selectin, von 
Willebrand factor), 
endocytosed 
molecules (FG); 
some contain 
exosomes 
 
High concentrations 
of small molecules 
important to cell 
activation (ADP, 
serotonin, calcium, 
magnesium, 
pyrophosphate, 
nucleotides) 
Components of 
endosomal-
lysosomal 
degradative 
pathway (acid 
hydrolases, 
cathepsins D and 
E) 
Development Fusion of vesicles 
budding from trans-
Golgi apparatus in 
megakaryocytes, or 
fusion of vesicles 
endocytosed from 
the plasma 
membrane 
 
Endogenous 
synthesis in 
megakaryocytes; 
may develop from 
fusion with endocytic 
vesicles 
Different 
ontogeny than 
alpha or dense 
granules, yet 
share common 
antecedents 
Disorders Gray platelet 
syndrome (variable 
bleeding diathesis; 
small abnormal 
vesicles; defect in 
formation or packing 
of alpha granule) 
Dense Storage Pool 
Deficiency 
(decreased thrombus 
formation, varying 
hemostatic defect) 
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Figure 2.1 Platelet Spreading Structures 
Platelets adhering to a matrix initially have a round morphology, but immediately 
extend fingerlike projections termed filopodia. Then lamellipodia are extended, 
which have been compared to webbing between a duck’s toes. Finally, the 
membrane fully extends to allow the platelet to cover a large surface area. 
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Figure 2.2 Platelet Activation Leading to Adhesion and Spreading or 
Aggregation 
Interaction of the platelet receptors GPIb and α2β1 with vWF or collagen on the 
exposed subendothelium leads to platelet activation and spreading on the 
subendothelium. Nearby platelets are recruited to form a thrombus and maintain 
hemostasis. Platelets can also be activated by soluble agonists (such as ADP), 
leading to platelet activation, granule secretion, and aggregation via binding and 
crosslinking GPIIb-IIIa on adjacent platelets. 
vWF 
Collagen 
GPIb 
α2β1 
GPIIb-IIIa 
FG 
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between GPIb and vWF can withstand very high shear rates, yet is characterized 
by fast association and dissociation rates, allowing slow platelet translocation 
along the vessel wall (Savage 1998). In the absence of VWF, GPIb can still 
initiate platelet tethering through other ligands, possibly thrombospondin-1 
(Bergmeier 2006, Jurk 2003). Under cases of low shear, a direct interaction 
between exposed collagen in the subendothelium and the platelet receptors αβ1 
and GPVI can support adhesion (Clemetson 2001).  
 
 Collagen and thrombin at the site of injury lead to platelet activation and 
inside-out signaling. As platelets then become activated, platelet integrins—
particularly GPIIb-IIIa—transition from their inactive conformation to an active 
conformation capable of binding agonists and transmitting intracellular signals. 
Activated integrins then bind their ligand on the vessel wall, develop filopodia and 
lamellipodia and become fully spread, and release the contents of their granules 
(see also Table 2.2). ADP and thromboxane A2 are among the granule contents 
released, promoting activation, and leading to the formation of a platelet plug and 
arrest of bleeding (Coleman 2004). 
 
 2.1.2.3   Aggregation. The major platelet protein involved in aggregation 
is GPIIb-IIIa (Fig 2.2), which is present in the platelet membrane and alpha 
granules, providing an extra pool of the integrin on the platelet surface upon 
platelet activation and granule release (Bennett 2005). Absent or dysfunctional 
GPIIb-IIIa leads to the bleeding defect Glanzmann thrombasthenia, characterized 
by platelets that are unable to form stable aggregates (Nurden 2005). Fibrinogen 
is the major GPIIb-IIIa ligand, capable of causing platelet aggregation by cross-
linking GPIIb-IIIa on adjacent platelets. Fibrinogen can also be converted to fibrin 
by thrombin; the resulting fibrin can cross-link with fibronectin, contributing to 
thrombus stability by anchoring the thrombi to the vessel wall.   
 
Thrombus formation is not abolished in fibrinogen-deficient mice, and 
other ligands for GPIIb-IIIa include vWF and FN (Ni 2000). vWF plays an 
essential role in occlusive thrombi formation at both arterial and venous shear 
rates (Nanda 2005, Ni 2000). Absence of vWF prevents additional thrombus 
growth and occlusion (Ni 2000). Additionally, in mice with reduced plasma FN 
levels, thrombus formation is highly defective, with increased emboli and delayed 
vessel occlusion (Ni 2003). However, this defect is specific to arteries, as no 
defect is found at venous shear (Matsukova 2006).  
 
 2.1.2.4   Cytoskeletal Rearrangement. In order for the platelet to be able 
to extend filopodia and lamellipodia, release its granules, and form stable 
aggregates, it must be able to rearrange its cytoskeleton. 
 
 Upon agonist exposure, platelets lose their discoid shape, becoming 
spherical and then rapidly extending filopodia and spreading on a surface. Shape 
change is driven by reorganization of the cytoskeleton and a doubling of the actin 
filament content (converted from globular actin) (Hartwig 2006). 
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 The membrane skeleton is first disassembled. It is released from actin and 
becomes centered in spread platelets. This is partly mediated by adducin, which 
is dissociated from spectrin and the barbed ends of actin. Adducin is inactivated 
by PKC-mediated phosphorylation, phosphatidylinositides, or calcium-
calmodulin-binding (Matsuoka 2000). 
 
 The cortical actin network is then disrupted. Gelsolin (20,000 per platelet) 
and cofilin (100,000 per platelet) function to fragment actin filaments, resulting in 
F-actin disassembly: gelsolin severs and caps barbed ends, while cofilin 
promotes the disassembly of actin from pointed ends. Increasing cytosolic 
concentrations of calcium triggers a conformational change in gelsolin, allowing it 
to bind and fragment actin. Gelsolin remains bound to the barbed end of actin 
until it is removed by polyphosphoinositides. Cofilin must be dephosphorylated to 
become active, requiring 15 to 60 seconds for maximal activation (Falet 2005). 
Gelsolin and cofilin, combined with the release of adducin from spectin-actin, 
remodel the membrane and actin cytoskeletons. 
 
 New actin filament assembly is initiated from the ends of actin filaments 
adjacent to the plasma membrane. Formation of lamellipodia, required for 
circumferential platelet spreading on the surface, requires a large amount of F-
actin. This need is met as platelets double their cellular F-actin content as 
filaments form and grow through barbed-end growth, via uncapping and 
fragmentation of barbed filament ends and activation of actin-related protein 2/3 
(Arp 2/3) (Hartwig 2006). Approximately 50% of gelsolin is dissociated from 
barbed ends of actin filaments, and the Arp 2/3 complex binds to actin near the 
barbed ends and nucleates a second filament. Upstream proteins and 
phospholipids, including Wiskott-Aldrich syndrome protein (WASP) family 
members and cortactin, regulate Arp 2/3 nucleation activity. Actin filament 
assembly is terminated via CapZ constitutively capping exposed barbed 
filaments; filopodial growth in cells can be promoted by modulating the activity of 
CapZ via proteins such as VASP/Mena (Gertler 1996, Mejillano 2004). 
 
 2.1.2.5   Clot Retraction. Platelet-mediated clot retraction is a necessary 
step for consolidation of a platelet thrombus. Retraction keeps the thrombus from 
falling apart by making it less susceptible to fibrinolysis (Denis 2007) and aids in 
wound closure, as the damaged edges are drawn together (Parise 1999).  
 
 Interactions between GPIIb-IIIa and fibrin (which is cleaved from 
fibrinogen by thrombin) results in outside-in signaling. Clot retraction is brought 
about as tyrosine residues on the cytoplasmic tail of GPIIb are phosphorylated 
(Phillips 2001, Shattil 2004), and cytoskeletal assembly and molecular 
translocations occur (Parise 1999). Clot retraction appears to be regulated 
through multiple pathways, including activation of PLCß and Rho kinase, which 
activate MLC kinase and inhibit MLC phosphatase, and PLCγ2 downstream of 
Src kinase (Suzuki-Inoue 2007).  This process is dependent on the contractile 
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protein thrombasthenin, as well as the interaction between actin and myosin 
(Suzuki-Inoue 2007). 
 
 
2.1.3   Platelet Receptors 
 
 2.1.3.1   G Protein-Coupled Receptors.  G-protein coupled receptors are 
one family of surface receptors involved in platelet activation (see Fig 2.3). These 
receptors contain seven membrane-spanning domains, and an intracellular and 
an extracellular terminus, and are also referred to as ―seven transmembrane 
receptors‖ or serpentine receptors. The intracellular domain of each of these 
receptors is coupled to a distinct heterotrimeric G protein, belonging to either the 
Gi, Gq, G12/13, or Gs families. Upon activation, the G protein triggers an 
intracellular signaling cascade resulting in platelet shape change, granule 
secretion, and platelet aggregation via integrin activation. 
 
 G-protein coupled receptors in human platelets include the ADP receptors 
P2Y1 and P2Y12, the thrombin receptors PAR-1 and PAR-4, and the 
thromboxane A2 receptors TPα and TPβ. 
 
 The P2Y1 receptor is coupled to Gq and phospholipase Cβ, which leads to 
activation of the small G proteins RhoA and Rac and Src kinases (Kahner 2006). 
Activation of PLCβ leads to hydrolysis of phosphatidylinositol 4,5-bisphosphate 
(PIP2) to inositol triphosphate (IP3) and diacyl glycerol (DAG), leading to calcium 
release, PKC activation, and weak, transient activation of GPIIb-IIIa (Gachet 
2006, Kahner 2006). P2Y1 is important for platelet shape change, the initial wave 
of reversible aggregation, thromboxane A2 generation, procoagulant activity, 
adhesion to immobilized fibrinogen, and thrombus formation under shear 
(Cattaneo 2005, Murugappan 2006).  
 
 P2Y12 is coupled to Gi2 (Gachet 2006). Activation leads to inhibition of 
adenylyl cyclase and inhibition of cytosolic cAMP concentration via the Gα 
subunit, and activation of phosphoinositide 3-kinase (PI3K), Akt/PKB, Rap1b, 
and src family kinases (Gachet 2006, Kahner 2006).  This receptor is important 
for stable platelet aggregation, in addition to sharing many of the same functions 
as P2Y1 (Cattaneo 2005, Murugappan 2006). The combined action of both 
receptors is needed for full platelet aggregation in response to ADP (Cataneo 
2005). P2Y12-blocking drugs such as clopidigrel and ticlopidine are clinically 
being used in the treatment of thrombotic disorders. 
 
 PAR1, which responds to low thrombin concentrations, and PAR4, which 
responds to higher thrombin concentrations, are activated by cleavage of an 
extracellular portion of the receptor. PAR4 is coupled to Gq and G12/13, and  
PAR1 is coupled to G1, G12/13, and Gi (Offermans 2006). Gq is coupled to 
PLCβ, especially β2 (leading to activation of PKC). G12/13 regulates the 
Rho/Rho kinase pathway, and Gi inhibits adenylyl cyclase (Offermans 2006). 
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Figure 2.3 Platelet Receptors 
A, G protein-coupled receptor; B, Integrin; C, Leucine-rich repeat protein; D, 
Immunoglobulin receptor; E, Tetraspanin. 
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 These steps lead to platelet cytoskeletal rearrangement, resulting in platelet 
shape change and platelet degranulation and adhesion (Offermans 2006). 
 
 TPα and TPβ are coupled to G13 and Gq, resulting in activation of Rho-
GEF and PLCβ. Both are important in platelet activation and shape change, and 
blockade of these receptors results in increased bleeding times and protection 
from thromboembolism (Murugappan 2004). 
  
 2.1.3.2   Integrins. Integrins are a family of integral cell-surface receptors 
made up of an alpha and a beta chain. Each chain consists of a large 
extracellular domain, a single transmembrane domain, and a short cytoplasmic 
domain (Fig 2.3). In mammals, 19 alpha and eight beta subunits combine to form 
24 integrins (Humphries 2000). They mediate contact between a cell and its 
environment and transmit signals across the plasma membrane. 
 
 Integrins undergo a highly regulated structural change, providing a 
transition from a bent state with a low affinity for ligand binding (inactive) to an 
extended, open state with a high affinity for ligand binding (active) (Adair 2002, 
Takagi 2002, Vinogradova 2002). Conformational changes resulting from ligand 
binding may result in the unmasking of specific epitopes, separate from the 
ligand-binding domain, on the integrin. These ―ligand-induced binding sites‖, or 
LIBS, offer a means to study integrin activation and ligand binding without 
occupying the ligand-binding domain. 
 
 Integrin signaling can be grouped into ―inside-out‖ signals, which control 
activation of the integrin, and ―outside-in‖ signals, resulting from ligand binding. 
Inside-out signaling results from a stimulus from another cell receptor (such as G 
Protein-Coupled Receptors), which leads to a stimulus acting on the cytoplasmic 
portion of the integrin and modifying the contacts between the cytoplasmic tails, 
leading to a change in the transmembrane domains and altering integrin affinity 
for ligand and integrin avidity (via integrin clustering on the cell surface). Outside-
in signals lead to recruitment of intracellular signaling molecules and cytoskeletal 
proteins, resulting in changes in platelet cytoskeleton and morphology (Arias-
Salgado 2005; Han 2006; Tadokoro 2003).  
 
 Platelets express several integrins, including αIIbβ3, which binds 
fibrinogen, fibrin, fibronectin, and von Willebrand factor; αvβ3, which binds 
vitronectin; α2β1, which binds collagen and laminin; α5β1, which binds 
fibronectin; and α6β1, which binds laminin. Of these, αIIbβ3, or GPIIb-IIIa, has 
the highest expression level, at 50,000-80,000 per platelet, and has been the 
most extensively characterized. 
 
 αIIb is composed of 1008 amino acids. The extracellular domain is 
composed of an N-terminal β-propeller domain, thigh domain, and two calf 
domains. β3 is composed of 762 amino acids, with an extracellular domain 
consisting of an A domain, plexin/semaphorin/integrin domain, four EGF 
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domains, and a membrane-proximal βTD domain (Xiong 2001). The extracellular 
domains of the α and β subunits combine to form an ellipsoid ―head‖ consisting of 
the β-propeller and A-domain, and two tails (Ma 2007). The transmembrane 
domains of each subunit form alpha helices that are believed to interact when the 
integrin is in a resting conformation (Adair 2002, Gottschalk 2005). The 
cytoplasmic tails form a complex between the membrane-proximal helices that is 
maintained by electrostatic and hydrophobic interactions; disruption of both these 
interactions leads to integrin activation (Ma 2006, Vinogradova 2002, Weljie 
2002). The membrane-distal regions of the cytoplasmic tails include a divalent 
ion-binding site, although the significance of this feature is uncertain (Haas 
1996). There is also a phosphotyrosine binding domain critical to integrin 
activation (Chen 1994, O’Toole 1995, Van der Geer 1995). More than 20 proteins 
have been identified as binding partners, most prominently talin (which links the 
integrin to the actin cytoskeleton and is critical in integrin-mediated focal 
adhesion formation) (Burridge 1996, Rees 1990). The cytoplasmic domains can 
also directly interact with the cytoskeletal proteins myosin, skelemin, filamin, α-
actinin, and F-actin; the adaptor/signaling proteins paxillin, Shc, and Grb 2; the 
protein kinases/phosphatases Src, Csk, Syk, ILK, FAK, and PP1c; and BiP, 
Calreticulin, and β3-endonexin (Ma 2007). αIIbβ3 can also bind with the 
transmembrane proteins CD36, CD47/IAP, CD98, and CD31, as well as the 
tetraspanins CD9, CD63, and CD151, although these interactions likely involve 
interactions with the transmembrane and extracellular domains (Ma 2007). 
 
 Inside-out signaling of GPIIb-IIIa is initiated by various platelet agonists, 
including thrombin, ADP, and collagen; each is capable of initiating inside-out 
signaling events, but they likely act cooperatively in a physiological environment. 
Agonist signaling leads to activated PKC, which regulates serine/threonine 
phosphorylation of GPIIb-IIIa. DAG, calcium, and PI3K regulate GPIIb-IIIa 
activation through Rab1b (a small GTPase of the Ras family), thus affecting 
binding of proteins, particularly talin, to the cytoplasmic domain of GPIIb-IIIa 
(Focosi 2007). The head domain of talin activates GPIIb-IIIa by binding to actin 
directly or indirectly through vinculin and α-actinin. The binding of β3-endonexin 
can also activate GPIIb-IIIa by binding to the β3 NITY motif. Integrin binding 
protein (IBP) binds to αIIb and appears to be involved in integrin activation 
(Platelets 2007). 
 
 Following inside-out signaling, the integrin GPIIb-IIIa becomes competent 
to bind ligands (fibrinogen, fibronectin, fibrin, etc). Ligand binding alters the 
conformation of the integrin, as well as inducing integrin clustering. This further 
encourages binding of cytoskeletal proteins leading to outside-in signaling. Src 
kinases, which are constitutively bound to β3, become activated through 
autophosphorylation. This leads to recruitment of Syk and tyrosine 
phosphorylation of PLCγ2, which is necessary for lamellipodial formation. SLP-76 
and Vav are also involved in regulation of PLCγ2. GPIIb-IIIa can also signal 
through Syk-independent cascades (Watson 2005). 
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 αvβ3 is structurally similar to GPIIb-IIIa, although its alpha chain has a 
slightly longer cytoplasmic tail (Suzuki 1986). Vitronectin, not fibrinogen, is the 
preferred ligand, although it can bind several RGD-containing ligands (including 
osteopontin and adenovirus penton base) (DiGiovine 2001). ADP appears to 
induce the high-affinity conformation (Bennett 1997, Helluin 2000). 
 
 α2β1 is the only platelet integrin to contain an I domain, which usually 
constitutes the primary ligand-binding interface (Emsley 1997). This integrin 
binds collagen types I-VI and XI (Kehrel 1995), leading to ADP release (Atkinson 
2003, Jung 2000) and phosphorylation of Src kinases, SLP-76, Syk, and PLC 
(Inoue 2003). Its absence leads to a bleeding disorder and reduced platelet 
response to collagen, although GPVI appears to be most important in collagen-
mediated platelet activation (Kehrel 1995, Nieuwenhuis 1985). 
 
 α5β1 is important for platelet interaction with the fibronectin matrix. Unlike 
the β3 integrins, it can support adhesion under static conditions in the absence of 
platelet activation (McCarty 2004), although adhesion strength may be increased 
upon activation (Garcia 1998). Ligand interaction is unable to promote tyrosine 
phosphorylation, calcium release, or shape change (McCarty 2004), limiting the 
role of this integrin to initiating the interaction of resting platelets with the 
extracellular matrix (Kasirer-Friede 2007). 
 
 α6β1 is a receptor for laminins, a component of basement membranes 
and the extracellular matrix (Sonnenberg 1988). Platelet activation is not 
necessary for ligand binding (Sonnenberg 1991), and binding to laminin does not 
appear to induce granule release or aggregation (Nigatu 2006), although it does 
induce filopodial formation (Chang 2005).  
 
 2.1.3.3   Leucine-Rich Repeat Proteins. GPIb-IX-V is a platelet adhesion 
receptor in the Leucine-rich repeat family. Its major function is initiating thrombus 
formation at high shear stress in flowing blood (Andrews 2003). It binds to vWF in 
the subendothelial matrix or plasma, as well as Mac-1 on neutrophils and P-
selectin on activated platelets and endothelial cells (Andrews 2003). Its absence 
or dysfunction leads to Bernard-Soulier syndrome, a rare but often severe 
bleeding disorder (Andrews 1997, Berndt 2001, Lopez 1998). 
 
 GPIb-IX-V consists of GPIbα disulfide-linked to GPIbβ, noncovalently 
complexed with GPIX and GPV in a 2:2:2:1 ratio (Fig 2.3) (Andrews 1997, Berndt 
2001, Lopez 1998). All components are members of the leucine-rich repeat 
family. The N-terminal portion of GPIbα, consisting of eight leucine-rich repeats, 
contains binding sites for vWF, Mac-1, P-selectin, α-thrombin, clotting factors 
XI/XIIa, and high-molecular-weight kininogen (Berndt 2001). 
 High shear results in GPIb-IX-V binding von Willebrand factor, which is 
rapidly secreted following platelet activation. Following binding, platelets become 
activated, leading to shape change, spreading, and granule secretion caused by 
cytoskeletal rearrangement, recruiting additional platelets to the developing 
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thrombus. GPIb-IX-V signal transduction, involving PI-3-kinase, Syk, Src, and 
ERK-1/2, leads to activation of GPIIb-IIIa, mediating platelet aggregation 
(Andrews 2003, Berndt 2001). 
 
 In order to be competent to adhere and signal, GPIb-IX-V undergoes 
multiple post-translational modifications. GPIb sulfation within the ligand-binding 
domain regulates adhesion to vWF (Dong 2001, Huizinga 2002, Shen 2000, Tait 
2002, Uff 2002) and thrombin (Berndt 2001); glycosylation of GPIb extends the 
ligand-binding domain and allows adhesion (Lopez 1998); cytoplasmic 
palmitoylation of GPIb and GPIX may regulate surface localization and 
association with other membrane proteins (Lopez 1998), and phosphorylation 
allows association with the signaling protein 14-3-3 (Bodnar 1999, Gu 1999).  
 
 2.1.3.4   Selectins. Selectins are proteins that bind glycoproteins and 
glycolipids in a calcium-dependent manner. They consist of an extracellular N-
terminal lectin domain adjacent to a domain homologous to epidermal growth 
factor, a variable number of short consensus repeats, a single transmembrane 
domain, and a C-terminal cytoplasmic domain (Sperandion 2006, Thomas 2006). 
 
 Platelets express the P-selectin, also known as CD62P. P-selectin is 
found in alpha granules of platelets and is rapidly mobilized to the cell surface 
upon platelet activation, where it binds to P-selectin glycoprotein ligand 1 (PSGL-
1) and Sialyl Lewis X-bearing glycoproteins (Smith 2007). The interaction 
between P-selectin and PSGL-1 allows platelet tethering to leukocytes under 
shear conditions and may contribute to leukocyte activation (Pitchford 2005, 
Zarbock 2006). 
 
 2.1.3.5   Immunoglobulin Receptors. Platelet Fc receptors mediate 
immune responses to IgG-containing complexes, implicating platelets in the 
adaptive immune response. These receptors contain immunoreceptor tyrosine-
based activation motifs (ITAMS) (Fig 2.3) (Reth 1989), and upon ligand binding, 
Src-family kinases phosphorylate tyrosine residues within the ITAM sequence, 
leading to recruitment and activation of Syk or ZAP-70 tyrosine kinase, initiating 
downstream signaling events (Fodor 2006). These responses seem to be 
regulated by the phosphoinositides PI4,5P2 and PI3,4,5P3 (Booth 2006). The 
activation pathways are inhibited by immunoreceptor tyrosine-based inhibitory 
motifs (ITIMs), which bind to the downstream tyrosine phosphatases (Jackson 
1997). In platelets, ITAM/ITIM signaling may be involved in hemostatic regulation 
as well as immune responses (Kasirer-Friede 2007).  
 
 Fc receptors are of particular importance in this study due to a localization 
and association of Fc receptors with tetraspanins. Anti-CD9 monoclonal 
antibodies crosslink CD9 to FcγRII, eliciting a potent activation response. While 
the functional relevance of this interaction has yet to be elucidated, tetraspanins 
have been shown to negatively regulate FcR signaling independently of co-
ligation, possibly through interactions within the tetraspanin web (Moseley 2005). 
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 Other receptors coupled to Fc receptors include GPVI, a collagen receptor 
(Berlanga 2000, Nieswandt 2000); GPIb-IX-V, a vWF receptor (Wu 2001, Arthur 
2005); and potentially C-type lectin receptor-2 (CLEC-2), which has an as-yet 
unknown function in platelets (Gross 2006).  
 
 2.1.3.6   Tetraspanins. The structure and function of tetraspanins is 
discussed more fully in the following sections. Tetraspanin function in platelets is 
summarized in Table 2.3. 
 
 Platelets express several tetraspanins, among them CD9, CD63, CD151, 
and TSSC-6 (Fig 2.3, Fig 2.4, and Fig 2.5). They are believed to modulate 
integrin function, and indeed, both antibody-blocking and knockout studies yield 
platelets with incomplete GPIIb-IIIa functioning. Megakaryocytes have been 
shown to contain the transcripts for the tetraspanins NET5 (TSPAN9) and 
TSPAN33, and these may also be expressed at the protein level in platelets 
(Senis 2007). 
 
 The tetraspanin CD63, with an apparent molecular mass of 30-60 kDa, is 
expressed on platelet lysosomes in resting platelets and is expressed on the 
platelet surface upon exocytosis triggered by platelet activation. CD63 has been 
studied by blocking with a monoclonal antibody. These platelets retained normal 
adhesion to fibrinogen, but platelet spreading, F-actin reorganization, 
redistribution of vinculin, extensive tyrosine phosphorylation, and phosphorylation 
of Focal Adhesion Kinase (FAK) were diminished. CD63 was also shown to be 
linked to PI 4-kinase type II (Israels 2005). 
 
 The impacts of TSSC-6 and CD151 in platelet function have been studied 
using knock-out mice. It is important to note that expression levels of integrin 
GPIIb-IIIa is unaffected in these knock-outs (Goschnick 2006, Lau 2004). 
 
 TSSC-6 (Tumor-suppressing subchromosomal transferable fragment 
cDNA 6) is localized to the cell surface and in intracellular pools in murine 
platelets. Mice that are deficient for TSSC-6 exhibit increased tail bleeding time, 
increased blood loss, and more rebleeds in a tail-bleeding assay, all features of 
unstable hemostasis. They also exhibit secondary instability in a ferric chloride 
oxidative injury model, showing greater time to vessel occlusion and a greater 
number of emboli forming during the observation period. Impaired ―outside-in‖ 
signaling of GPIIb-IIIa was evident, as these platelets had delayed clot retraction, 
defective spreading, and reduced aggregation at low concentrations of agonist 
(≤150 μM PAR-4, 5 μg/ml collagen). However, ―inside-out‖ signaling was 
unaffected, as knockout mice showed normal fibrinogen binding, normal binding 
of an activation-dependent antibody to GPIIb-IIIa, and normal alpha granule 
release (Goschnick 2006). 
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Table 2.3 Summary of Tetraspanins in Platelet Function 
 
 
Tetraspanin 
 
CD9                  CD9 
 
CD151 
 
CD63 
 
TSSC-6 
 
Method 
Studied 
 
knock-out antibody 
blocking 
 
knock-out antibody 
blocking 
knock-out 
Species 
 
Mouse human mouse human mouse 
Aggregation Unknown unknown reduced in 
response to 
PAR4, 
collagen, 
ADP 
 
 reduced in 
response to 
PAR4 
<150 uM, 
Collagen 5 
ug/ml. 
 
Adhesion 
 
Unknown unknown unaffected unaffected unaffected 
Spreading 
 
Unknown unknown impaired Impaired impaired 
Ligand Binding Unknown unknown normal 
soluble FG 
binding 
 
unknown normal 
soluble FG 
binding 
Activation Unknown unknown unaffected unaffected unaffected/ 
similar P-
selectin 
expression 
 
Cytoskeleton Unknown unknown unknown impaired F-
actin 
reorganiz-
ation, vinculin 
distribution 
 
unknown 
Signaling 
Molecules 
Unknown unknown normal 
levels of 
calcium and 
IP3 
reduced 
phosphoryl-
ation of FAK. 
IP’s PI4-
kinase type II. 
 
unknown 
Clot Retraction 
 
Unknown unknown impaired unknown impaired 
Other insight possible 
compen- 
sation by 
another 
tetraspanin 
or integrins 
is unknown 
activation 
of FcRII 
makes 
interpret-
ation of 
data 
difficult 
  increased 
tail bleeding 
time/ 
rebleeding, 
unstable 
platelet 
thrombi/ 
more emboli 
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Figure 2.4 Schematic of Tetraspanin CD9 
TM, Transmembrane domain; EC, extracellular loop. Numbers refer to amino 
acid residues. C-C, disulfide bond between cysteine residues. The area circled in 
red corresponds to the binding site for mAb7/mFab7.
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A  
 
B 
  
 
 
Figure 2.5 Tetraspanin Web in Platelets 
A, Resting platelet membrane, expressing FcR, CD9, a bent (inactive) GPIIb-IIIa, 
CD151, and TSCC6.  B, Activated platelet membrane. GPIIb-IIIa now assumes 
an extended conformation, capable of ligand binding. CD63 is also brought to the 
surface, in association with CD9 and GPIIb-IIIa.
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 CD151, also known as PETA-3 (platelet endothelial tetraspan antigen-3), 
is physically and functionally associated with GPIIb-IIIa and modulates its 
―outside-in‖ signaling. CD151-deficient mice have delayed clot retraction; 
reduced aggregation to 500 μM PAR-4, 20 μg/ml collagen, and 10 μM ADP; and 
normal adhesion but incomplete spreading on fibrinogen, including reduced 
number of filopodia per platelet. Inside-out GPIIb-IIIa signaling was normal, as 
these platelets had normal FG binding, normal binding of an activation-
dependent antibody to GPIIb-IIIa, normal alpha and dense granule secretion, and 
normal increases in cytosolic-free calcium and IP3 levels (Lau 2004). 
 
 In spite of CD9 expression on the platelet surface being greater than other 
tetraspanins, and being greatly studied, it is still poorly understood. It is localized 
to the platelet surface membrane and alpha granules (Cramer 1994). Studies 
with antibody ligation to CD9 have been inconclusive due to the linkage to the 
low-affinity immunoglobulin G receptor, FcγRIIa, in human platelets (Kuruda 
1995, Qi 1996), although one study suggests that CD9 regulates platelet function 
independently of FcγRIIa (Wu 2000).  
 
 CD9 knock-out mice have not shown any critical platelet defects; however, 
expression levels of other tetraspanins, integrins, and surface proteins have not 
been characterized, allowing the possibility of compensation. Additionally, studies 
involving CD9 knock-out platelets have not utilized low concentrations of 
agonists, which would be suggested based on studies with TSSC-6 knockout 
platelets. 
 
 CD9 (see Fig 2.4 and Fig 2.5) is proposed to have roles in platelet 
aggregation and spreading. It may facilitate platelet functions via its association 
with GPIIb-IIIa or through direct ligand binding, as fibronectin has been shown to 
be a ligand for CD9 (Longhurst 2002). 
 
 
2.2   Tetraspanins 
 
 
2.2.1   Tetraspanin Structure 
 
 Tetraspanins are integral membrane proteins containing four 
transmembrane alpha-helices (TM1, TM2, TM3, and TM4), two extracellular 
loops (EC1 and EC2), and short intracellular amino and carboxy termini 
(Berditchevski 2001, Boucheix 2001, Hemler 2001).  EC1, also known as the 
small extracellular loop, is flanked by TM1 and TM2, while EC2, also known as 
the large extracellular loop, is flanked by TM3 and TM4.  
 
Proteins are identified as tetraspanins based on a shared overall structure 
distinct from other proteins with four transmembrane domains and the 
conservation of specific amino acid residues in their transmembrane domains 
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and the second extracellular loop (Hemler 2001, Maecker 1997). These 
characteristic motifs include the conserved cysteine-cysteine-glycine (CCG)  
sequence in EC2, which is involved in two of the two to four disulfide bridges 
observed in EC2 of all tetraspanins (Seigneuret, 2001). TM1, TM2, and TM3 
consist of heptad repeat motifs, containing highly conserved asparagine and 
glycine in TM1 and TM2, and conserved leucine and glutamate/glutamine in 
TM3. Heptad repeat motifs are noticeably absent in TM4, although it contains 
conserved polar amino acids (Kovalenko 2005). There is a highly conserved 
asparagine-glycine-glycine motif in EC1 (Kovalenko 2005). 
 
 EC2, and rarely EC1, are glycosylated at one or more N-glycosylation 
sites, contributing to the overall tetraspanin size that ranges from 20 to 70 kDa 
(Yunta 2002). 
 
 Crystal structures of full-length tetraspanin proteins have not been 
generated, owing to inherent properties of membrane proteins; however, the 
crystal structure of the EC2 loop of CD81 has been solved (Kitadokoro 2001). 
This showed five alpha-helices arranged in ―stalk‖ and ―head‖ domains, and it is 
believed that these structural features are consistent among all tetraspanins 
(Kitadokoro 2001). 
 
 Tetraspanins are evolutionarily conserved. In addition to mammals, they 
have been found in Schistosomes (Wright 1990), early metazoans (Adell 2004), 
fungi (Gourgues 2002), and nematodes (Moribe 2004).  Currently, more than 30 
tetraspanins have been identified. 
 
Tetraspanins are expressed in all human cell types, and most cells 
generally express multiple tetraspanins (Levy 2005). Tetraspanins may be 
expressed on both the cell surface and on granular membranes (Israels 2005). 
Some tetraspanins—such as CD9 and CD81—are expressed in almost all cell 
types, while others are more restricted— CD37 in B cells (Schwartz-Albeiz 1988), 
RDS/peripherin in retina (Travis 1991), uroplakins in bladder epithelium (Walz 
1995), and CD53 in lymphoid-myeloid cells (Maeker 1997). 
 
 
2.2.2   Tetraspanin Web 
 
 Tetraspanins have been implicated in a wide variety of cell processes. 
This is likely the result of interactions between tetraspanins and other associated 
proteins within tetraspanin webs (which is also known as tetraspanin 
microdomains, tetraspanin enriched microdomains, or tetraspanin complexes) 
(see also Fig 2.5).  
 
 Tetraspanins have the ability to associate with a wide variety of membrane 
proteins.  Generally, the extracellular domains—mainly EC2—interact with 
laterally associated proteins or soluble ligands, the cytosolic regions associate 
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with cytoskeletal or signaling molecules, and the transmembrane domains 
interact with other proteins necessary for maintenance of the tetraspanin web 
(Levy 2005). Thus, the tetraspanin web acts as a molecular facilitator, organizing 
membrane proteins and coupling receptors to signaling pathways (Levy 2005). 
 
 In differing cell types, the tetraspanin web is composed of different 
tetraspanins and partner proteins. It is unclear whether all the tetraspanins in a 
certain cell are associated with each other. 
 
 Within the tetraspanin web, specific tetraspanins directly associate with a 
partner membrane protein (frequently a member of the integrin or 
immunoglobulin superfamilies) and other tetraspanin proteins. These 
tetraspanins also directly associate with a particular partner protein. Primary 
interactions between tetraspanins and partner proteins are believed to be 
mediated through extracellular domains, in particular EC2, due to resistance to 
Triton-X 100 disruption. The majority of tetraspanin interactions with other 
membrane proteins cannot withstand Triton-X 100 treatment, but can withstand 
milder detergents and are termed secondary interactions (Serru 1999).   
 
 Palmitoylation of intracellular cysteine residues plays an important role in 
tetraspanin-tetraspanin interactions; abolishment of this palmitoylation reduces a 
tetraspanin’s interaction with other tetraspanins (Charrin 2002, Yang and Claas 
2002). Palmitoylation of partner proteins also contributes to their incorporation 
into the tetraspanin web (Yang and Kovalenko 2004). Palmitoylation provides a 
regulatory mechanism to rearrange the tetraspanin web in response to 
stimulation (Dempsey 1996). 
 
 The tetraspanin web also includes interactions with cytoskeletal and 
signaling molecules. These signaling molecules include Rho GTP-binding 
proteins (Schwartz 2000), G protein-coupled receptors and their intracellular 
associated heterotrimeric G-proteins (Little 2004), phosphatidylinositol 4-kinase 
(Berditchevski 1997, Yauch 1998), and PKC isozymes (Zhang 2001). The 
tetraspanin web is linked to the actin cytoskeleton via EWI-2 and EWI-F (Sala-
Valdes 2006). 
 
Tetraspanin-enriched membrane domains are physically and functionally 
separate from lipid rafts, although they share some characteristics (Claas 2001, 
Hemler 2003). Both can associate with cholesterol and gangliosides and can be 
recovered from low-density membrane fractions of sucrose gradients. However, 
tetraspanin webs and lipid rafts exhibit differences in membrane solubility and 
have different protein content (lipid rafts often contain GPI-linked proteins and 
caveolin, which are rarely found in tetraspanin webs) (Berditchevski 2002, Foster 
2003, Hemler 2005, Yauch 2000). Lipid rafts may associate with the tetraspanin 
web under certain conditions, thereby facilitating signal transduction (Israels 
2007). 
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 With specific regard to the tetraspanin CD9, interactions have been shown 
with the integrins α3β1 (Yanez-Mo 1998), α4β1α6β1,α5β1,αIIbβ3 (GPIIb-IIIa), 
and precursor β1 (Yunta 2002); the growth factor receptors TGF-α and HB-EGF 
(Lagaudriere-Gesbert 1997); immunoglobulin superfamily members FRPP and 
EWI-2 (Stipp 2001); CD36 and CD9P-1 (Miao 2001), CD19 (Horvath 1998), and 
CD46 (Yunta 2002); the signaling molecules PKC and PI4K (Boucheix 2001); 
and the soluble ligands FN (Longhurst 2002), and PSG 17 (Waterhouse 2002). 
Many more protein partners will likely be identified in the future. 
 
 
2.2.3   Tetraspanin Function 
 
 It is unknown whether tetraspanins alter integrin conformation or affinity 
for ligand. In addition, for the most part, tetraspanins do not affect static cell 
adhesion. However, other integrin-dependent events—migration, spreading, and 
cell morphology, among others—can be greatly affected by tetraspanins.  
 
 2.2.3.1   Cell Motility. Tetraspanins have been found to be expressed in 
motility-related structures, such as lamellipodia, and involved in cell motility. 
 
 In keratinocytes, the tetraspanins CD9 and CD81 are highly expressed in 
filopodia at lateral and apical surfaces, as well as in the footprints and rippings of 
motile keratinocytes, suggesting a role in keratinocyte motility. In a wound 
healing assay, cell migration was inhibited with antibodies to CD9 and CD81, and 
to a lesser extent, to CD151, perhaps via involvement in integrin recycling during 
keratinocyte migration (Penas 2000). 
 
 When HT-1080 cells are transfected with CD9, lamellipodia formation is 
significantly decreased, and this effect was reversed upon antibody ligation. CD9 
was able to influence lamellipodial formation by downregulating WAVE2 (Huang 
2006). 
 
 In Chinese hamster ovary cells, expression of CD9 enhances cell motility 
on fibronectin. This is likely via a direct interaction between CD9 EC2 and FN 
(Longhurst 2002). 
 
 2.2.3.2   Tumor Cell Metastasis. Tetraspanins CD9 and CD82 are 
considered metastasis suppressors in solid tumors (Wright 2004). These 
tetraspanins are downregulated in progression of several cancers, including non-
small cell lung, breast, pancreas, colon, and prostate, and decreased expression 
of these tetraspanins result in poorer prognosis (Boucheix 2001, Saito 2006). 
 
The tetraspanin CD82 (also known as KAI1) tumor metastasis suppressor 
activity is believed to be through the association of CD82 with the EGF receptor 
tyrosine kinase, which accelerates ligand-induced clearance of EGF receptor 
from the cell surface (Bienstock 2001). 
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Adenoviral transduction of CD9 or CD82 into lung tumor cells, whether via 
direct implantation or through intratracheal administration, dramatically reduced 
metastasis to mediastinal lymph nodes (Takeda 2007). However, over-
expression of CD9 in human prostate cancer cell lines did not suppress 
metastatic properties, suggesting that CD9 partner proteins may be needed for 
full anti-metastatic effect (Zvieriev 2005). 
 
 2.2.3.3   Cell Proliferation and Differentiation. The tetraspanin TSSC-6 
colocalizes into domains on T cells containing T cell molecules involved in T cell 
stimulation, such as CD4 and CD8. Deletion of TSSC-6 yields mice with normal 
lymphoid development, yet T cells showed elevated T cell receptor-dependent 
proliferation in vitro in response to concanavalin A, anti-CD3, and anti-CD28 
(Tarrant 2002). 
 
 Proliferation of T lymphocytes from CD81-deleted mice is also enhanced 
in response to various stimuli. In B cells, deletion of the tetraspanin CD81 results 
in diminished numbers of a subset of B cells (Miyazaki 1997). CD81 is also 
involved in driving helper T cells toward polarized Th2 differentiation (Deng 2000, 
Maecker 1997). 
 
 In the brain, deletion of CD81 results in mice with increased numbers of 
astrocytes and microglia, resulting in greatly enlarged brains (Geisert 2002). 
CD81 may control astrocyte and microglia proliferation in a cell-cell contact-
dependent manner; neurons inhibit proliferation by interacting with CD81 on 
cultured astrocytes (Kelic 2001). 
 
 Tetraspanins have been implicated in growth factor signaling as well. CD9 
regulates pro-TGFα, pro-HB-EGF, and pro-amphiregulin, all of which are 
membrane-bound agonists for the EGF receptor (Inui 1997, Shi 2000). CD9 is 
necessary for HB-EGF mitogenic activity (Nakamura 2000).  
 
 During osteoclast differentiation, CD9 expression increases during 
RANKL-induced osteoclastogenesis. A CD9-neutralizing antibody suppressed 
RANKL-induced multinucleated osteoclast formation and mRNA expression of 
osteoclast differentiation marker genes, and this was shown to be through 
regulating long-term phosphorylation of p44/42 MAPK (Yi 2006). 
 
 CD9 is also involved in megakaryocyte differentiation. In hematopoietic 
stem cells, those with the highest expression of CD9 are committed to the B-
lymphoid or megakaryocytic lineages, and expression of CD9 is found to precede 
expression of CD41 in megakaryocyte precursors. Antibody ligation to CD9 
inhibited the in vitro terminal differentiation of human CD34+ cells into 
megakaryocytes. It was observed that antibody ligation deeply altered membrane 
structures (demarcation membranes and heterogeneous multivesicular body 
membranes) of these cells (Clay 2001).   
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 2.2.3.4   Cellular Morphology. The tetraspanins peripherin/RDS and 
ROM-1 are expressed in the retina and have specialized roles in maintaining the 
outer segment discs in their characteristic flattened, parallel layers (Kohl 1998). 
Point mutations in the EC2 domain are associated with various human retinal 
dystrophies (Kohl 1998) and disruption of the peripherin/RDS tetraspanin gene 
causes retinal degeneration (Connell 1991). 
 
 Mutation of a CD151 site influencing integrin interaction resulted in mutant 
cells lacking integrin-dependent spreading and cellular cable morphology on 
Matrigel (Kasarov 2002). Another mutation on CD151, affecting palmitoylation, 
resulted in cells that could interact with integrins but not with other tetraspanins. 
This resulted in kidney epithelial cells transitioning from a fibroblastic morphology 
to an epithelial morphology (Yang 2002). A third mutation in CD151, in the C-
terminal tail (abolishing a theoretical linkage to cytoskeletal or cytoplasmic 
signaling molecules), altered integrin-dependent cell spreading, cellular cable 
formation functions, and adhesion strengthening (Lammerding 2003, Zhang 
2001). 
 
 In small cell lung cancer cells, CD9 expression is usually diminished. 
Increased expression of CD9 suppressed neurite-like process outgrowth and 
promoted apoptotic death. This was found to be via PI3K/Akt signaling (Saito 
2006). 
 
 2.2.3.5   Virus-Induced Syncitia Formation. The tetraspanins CD9, 
CD81, and CD82 have been implicated in virus-induced syncitia formation 
(Fukudome 1992, Willet 1997). 
 
 In human T lymphoblasts, antibody ligation of either CD81 or CD9 
enhanced syncitia formation induced by HIV-1 envelope proteins and viral entry 
into the lymphoblasts. In addition, decreased CD81 and CD9 expression 
increased syncitia formation and viral entry, while overexpression resulted in 
decreased susceptibility to syncitia formation (Gordon-Elonso 2006). 
 
 2.2.3.6   Intracellular Vesicles. The tetraspanin web may be adapted to 
facilitate vesicular fusion and fission with the cell membrane (Hemler 2003). 
Tetraspanin expression is enriched in the endocytic pathway. Exosomes from B 
cells are enriched for CD37, CD53, CD63, CD81, and CD82 by 7- to 124-fold 
(Escola 1998). Jurkat cell activation results in CD81 removal from the cell surface 
in parallel with release of CD81-containing exosomes (Fritzsching 2002). 
 
 2.2.3.7   Cell-Cell Interactions. Investigations into megakaryocyte and 
proplatelet formation suggest that CD9 is involved in altering membrane 
structures, suggesting a role in membrane reorganization, especially cell fusion 
(Clay 2001). 
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 Fluorescence microscopy has revealed that CD9, while ubiquitously 
expressed across the cell membrane, is increased at areas of cell-contact, 
suggesting a role in cell-cell interactions. This phenomena is observed both in 
cells natively expressing CD9, such as kidney epithelium and breast cancer cells, 
(Nakamura 1995, Yang 2006) and in cells that have been transfected with CD9 
(Yang 2006). Additionally, CD9, CD81, and CD151, along with integrins, 
accumulate at keratinocyte cell junctions (Penas 2000). 
 
 One of the most striking phenotypes of the CD9 knock-out mouse model is 
the reduced fertility in females. CD9 has been shown to have a crucial role on 
oocytes during sperm-egg fusion—CD9 knock-out mice oocytes are deficient in 
their ability to fuse with sperm (Kaji 2000, La Naour 2000, Miyado 2000). 
Furthermore, anti-CD9 antibodies can inhibit sperm-egg fusion (Chen 1999, La 
Naour 2000, Miller 2000), and CD9 recombinant proteins corresponding to 
residues 173-175 in CD9 EC2 partially inhibit fusion when added to the oocyte 
prior to insemination but not when preincubated with sperm, showing that CD9 is 
probably not a sperm receptor, but more likely influencing other members of the 
tetraspanin web (Zhu 2002).  
 
 CD9 also appears to be involved in implantation, as CD9 is variably 
expressed in the murine uterus depending on the stage of implantation, and was 
upregulated in an ovarian steroid hormone-dependent manner (Weimin 2007). 
 
 In human ova, antibody ligation of CD9, prior to zona removal, prevented 
the clustering of 61 integrin clustering and gamete fusion. Antibody ligation to 
CD151 is able to partially inhibit sperm-egg fusion. This suggests that these 
tetraspanins are able to control the redistribution of membrane proteins into the 
clusters necessary for gamete fusion (Ziyyat 2006). 
 
 
2.2.4   Tetraspanin CD9 
 
CD9 was shown to be localized to the p region of chromosome 12 (Benoit 
1991). cDNA from a megakaryocyte library showed that CD9 is comprised of 
eight exons, producing a protein with 228 amino acids (Lanza 1991).  
 
CD9 expression is most abundant on cells of megakaryocyte lineage—
megakaryocytes and platelets (Boucheix 1988, Brisson 1997, Deng 1983, 
Jennings 1994). It is also expressed on macrophages (Wang 2002), eosinophils 
(Fernvik 1995), basophils (Fureder 1994), marginal zone B cells (Won 2002), 
endothelial cells (Barreiro 2005, Klein-Soyer 2000), ectodermal nervous tissue 
(Banerjee 1997), smooth muscle cells (Scherberich 1998, Scherberich 2002), 
and oocytes (Ziyyat 2006). 
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CHAPTER 3   METHODOLOGY 
 
 
3.1   Materials 
 
 Nonspecific mouse IgG, Fab fragment, and goat anti-mouse Fc specific 
F(ab’)2 fragment were obtained from Jackson Immunolaboratories (West Grove, 
PA). Adenosine 5’-diphosphate (ADP), tetramethyl rhodamine isothiocyanate 
(TRITC)-labeled phalloidin, fluorescein isothiocyanate (FITC)-conjugated goat 
anti-mouse antibody, fluorescein isothiocyanate (FITC)-conjugated goat anti-
mouse Fab, nonspecific mouse IgG1, -octylglucopyranoside, and other general 
reagents were purchased from Sigma Chemical Company (St. Louis, MO). FITC-
labeled anti-CD9 antibody, clone ML-13, was purchased from BD Biosciences 
(San Jose, CA). PE-labeled anti-CD63 and anti-P-selectin were from BD 
Pharmingen (San Jose, CA). Collagen was purchased from Chronolog Corp 
(Havertown, PA) and TRAP (thrombin receptor agonist peptide) was purchased 
from Peninsula Laboratories (San Carlos, CA). Eptifibatide was provided by 
Schering-Plough (Kenilworth, NJ). Fibrinogen was from Enzyme Research 
Laboratories (South Bend, IN) and fibronectin was from Gibco (Carlsbad, CA). 
Gelcode Blue Stain was from Pierce (Rockford, IL) and Coomassie blue was 
from BioRad (Hercules, CA). mAb7 was obtained from mouse ascites and 
purified by Affi-gel Protein A column (BioRad, Hercules, CA). mFab7 was 
generated and purified using Immunopure® Fab Preparation Kit (Pierce, 
Rockford, IL) and purified Fab underwent buffer exchange into phosphate-
buffered saline (PBS), pH 7.4, using Zeba™ Desalt Spin Columns (Pierce, 
Rockford, IL). Human coagulation Factor XIII was from Calbiochem (San Diego, 
CA). Vectashield mounting media was purchased from Vector Laboratories 
(Burlingame, CA). Superfrost microscope slides and microscope cover glass 
were from Fisher Scientific (Pittsburgh, PA). Anti-fibrinogen antibody was 
obtained from The Binding Site (San Diego, CA). Protease inhibitor cocktail 
tablets were from Roche (Basel, Switzerland). 
 
 
3.2   Tetraspanin Expression on Resting and Activated Platelets 
 
 Flow cytometry was used to assay the levels of the tetraspanins CD9, 
CD63, and CD151; the integrin GPIIb-IIIa, and the protein GPIb on the surface of 
resting and activated platelets (See Fig 3.1). Blood was obtained from healthy 
adult donors into 0.1 M buffered citrate as an anticoagulant. PRP was prepared 
(Table 3.1) and diluted with PPP to a final platelet count of 250,000 platelets/μl. 
Platelets were either allowed to remain resting or were activated with 10 μM ADP 
or 2 μM TRAP. Platelets were then incubated with primary antibody for 30 
minutes at 37ºC (R&D monoclonal anti-human CD151 antibody, catalog 
#MAB1884 for CD151; 10E5 and 7E3 for GPIIb-IIIa; 6D1 for GPIb; BD 
Pharmingen Purified mouse anti-human monoclonal antibody, catalog #3556019 
for CD63; mAb7 for CD9; and mIgG, Sigma MOPC-21, as a negative control). 
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Figure 3.1 Measurement of Surface Proteins by Flow Cytometry 
Platelets are incubated with fluorescently-labeled antibodies which bind a specific 
surface protein. Platelets are incubated with the antibody, and level of 
fluorescence is measured by a flow cytometer. 
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Table 3.1 Preparation of PRP and PPP 
 
 
Step 
 
Instructions 
 
1 Whole blood is obtained by venipuncture into 0.1 M buffered citrate. 
Other anticoagulants may be used as indicated. 10 ml total volume is 
used per 15 ml tube. 
 
2 Tubes are centrifuged at 135 x g for 15 minutes. Platelet-rich plasma 
(PRP), the top layer, is removed and set into a clean 15 ml tube. PRP 
must be carefully removed to avoid contamination with white blood 
cells in the buffy coat. 
 
3 The remaining blood is centrifuged at 2,500 x g for 15 minutes. 
Platelet-poor plasma (PPP), the top layer, is carefully removed and 
set into a clean 15 ml tube.  
 
4 PRP is counted with a Coulter Counter, and diluted with PPP to the 
desired concentration. 
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Ten microliters of each sample were transferred to a microfuge tube with 
500 μl filtered PBS+10 μl goat anti-mouse FITC-labeled antibody, and samples 
were incubated for ten minutes at room temperature prior to data collection using 
the flow cytometer (using the Platelet Green template). This was repeated using 
ten normal, healthy adult donors. 
 
 
3.3   Association of CD9 and GPIIb-IIIa in Resting and Activated Platelets 
 
 
3.3.1   Co-Immunoprecipitation 
  
 Whole blood was obtained by venipuncture and mixed with ACD as an 
anticoagulant (Table 3.2). Platelets were washed twice with CGS (Table 3.3), 
resuspended in platelet lysis buffer containing 1% CHAPS (Table 3.4), and lysed 
for 20 minutes on a rocker at 4º C. Samples were clarified by centrifugation at 
18,300 x g for 10 min at 4º C, discarding the pellet. Protein concentration was 
measured using Biorad Detergent-Compatible Assay kit and adjusted to 1.5 
mg/ml. One ml lysate and 75 μl Protein A/G beads were added to each of five 
eppendorf tubes, and samples were incubated for 60 minutes on a rocker at 4º C 
and then precleared by centrifugation at 18,300 x g for one minute. Supernatants 
were collected and transferred to five new tubes, to which was added either 5 μg 
D3, 5 μg D3 + 3 mM eptifibatide, 5 μg AP3, 5 μg mAb7, or 5 μg mIgG (MOPC-
21) as a negative control. Samples were incubated with primary antibody for one 
hour on a rocker at 4ºC. 75 μl Protein A/G beads were added to each tube and 
incubated for 60 minutes on a rocker at 4º C. Samples were centrifuged three 
times at 18,300 x g with cold lysis buffer, discarding the supernatant after each 
wash. Samples were boiled with fresh non-reduced sample buffer (Table 3.5), 
separated on a 5%-20% gradient separating gel (Table 3.6 and Table 3.7), and 
transferred to a PVDF membrane. Membranes were blocked by rocking with 5% 
nonfat dry milk in 0.1% TBS-Tween at room temperature for 60 minutes then 
incubated with primary antibody in 5% nonfat dry milk in TBS-Tween overnight at 
4º C (mAb7 is used to detect CD9, and C3 is used to detect IIb) (Table 3.8). 
Bound antibodies are labeled with HRP-labeled sheep anti-mouse antibody and 
detected with ECL-PLUS kit prior to development onto photo paper. 
 
 
3.3.2   Confocal Analysis 
 
Coverslips, in individual wells of a 20-well tissue culture plate, were coated 
with 500 μg/ml FG, 50 μg/ml plasma FN, fibrin, or fibrin-FN overnight at 4ºC 
(Table 3.9). Coverslips were then blocked with 1 ml 20 mg/ml BSA in PBS for 2 
hours at 37ºC and washed 3x with PBS (Table 3.8). 500 μl of washed platelets 
(Table 3.10), at 1x107 platelets/ml in HEPES-Tyrode buffer (Table 3.11), were 
incubated 1 hour on the coverslips. Non-adherent platelets were removed by 
washing 3x with HEPES-Tyrode buffer. GPIIb-IIIa was stained with D3 for 30  
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Table 3.2 Anticoagulants 
 
 
Material 
 
ACD 
 
0.1 M Buffered Citrate 
 
Sodium citrate 
 
0.085 M 0.06 M 
Dextrose 
 
0.1 M --- 
Citric acid 0.07 M 0.04 M 
 
 
 
 
Table 3.3 CGS 
 
 
Material 
 
Concentration 
 
Sodium Citrate 
 
0.01 M 
Dextrose 
 
0.03 M 
NaCl 
 
0.12 M 
pH 6.5 
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Table 3.4 Lysis Buffer for Immunoprecipitations 
 
 
Amount 
 
Material 
 
10 mM 
 
HEPES 
200 mM 
 
NaCl 
1% 
 
CHAPS or BRIJ-98, as indicated 
5 mM 
 
MgCl2 
2 mM 
 
NaF 
100 mM 
 
Na4P2O7 
1 per 10 ml Protease inhibitor tablet 
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Table 3.5 Formula for 1/3x NR Sample Buffer 
 
 
Amount 
 
Material 
 
1.8 ml 0.5 M Tris, pH 6.8 
 
1.6 ml 
 
Glycerol 
 
0.32 g 
 
SDS 
 
0.32 ml 
 
Bromophenol blue 
 
Q.S. to 4 ml 
 
dH2O 
 
 
 
 
Table 3.6 Formulas for SDS-PAGE Gels 
 
 
Material 
 
5% Separating 
Gel 
 
20% Separating 
Gel 
 
 
Stacking Gel 
Distilled H2O 22.5 ml 0.301 ml 6.1 ml 
 
Glycerol 
 
334.4 μl 
 
1.1 ml 
 
---- 
 
1.5 M Tris, pH 8.8 
 
10.0 ml 
 
5 ml 
 
---- 
 
0.5 M Tris, pH 6.8 
 
---- 
 
---- 
 
2.5 ml 
 
10% SDS 
 
401.2 μl 
 
200.7 μl 
 
100 μl 
 
30% 
acrylamide/bis 
 
6.7 ml 
 
13.4 ml 
 
1.3 ml 
 
TEMED 
 
10 μl 
 
5 μl 
 
10 μl 
 
10% APS (fresh) 
 
120.3 μl 
 
61.5 μl 
 
50 μl 
 
38 
Table 3.7 Formula for Western Blot Buffers 
 
 
Material 
 
Running Buffer 
 
Blot (Transfer) Buffer 
 
TRIS 18 g 12.2 g 
 
Glycine 
 
86.4 g 
 
57.6 g 
 
SDS 
 
3.0 g 
 
4.0 g 
 
Methanol 
 
---- 
 
800 ml 
 
Total volume 
 
3 L 
 
4 L 
 
 
 
 
Table 3.8 Buffered Saline Recipes 
 
 
Material 
 
Phosphate-buffered 
saline (PBS) 
 
Tris-Buffered Saline 
(TBS) 
 
Na2HPO4 0.14 M ---- 
 
NaH2PO4 
 
0.06 M 
 
---- 
 
NaCl 
 
2.87 M 
 
0.15 M 
 
Tris 
 
---- 
 
0.01 M 
 
pH 
 
7.4 
 
7.4 
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Table 3.9 Fibrin and Fibrin-Fibronectin Matrix Components 
 
 
Material 
 
Fb 
 
FbFN 
 
Fibrinogen 2.4 mg/ml 2.4 mg/ml 
 
Fibronectin 
 
0 
 
240 μg/ml 
 
CaCl2 
 
0.02 M 
 
0.02 M 
 
NaCl 
 
0.15 M 
 
0.15 M 
 
Tris-HCl, pH 7.5 
 
 
0.05 M 
 
0.05 M 
Human coagulation factor XIII 
 
5 μg/ml 5 μg/ml 
Thrombin 2 units/ml 2 units/ml 
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Table 3.10 Preparation of Washed Platelets 
 
 
Step 
 
Instructions 
 
1 Whole blood is obtained by venipuncture into ACD, at a ratio of 1.4 ml 
ACD to 8.6 ml whole blood. 10 ml total volume is used per 15 ml tube. 
 
2 Blood is centrifuged at 135 x g for 20 minutes. Platelet-rich plasma, 
the top layer, is removed and set into a clean 15 ml tube. PRP must 
be carefully removed to avoid contamination with white blood cells in 
the buffy coat. Red and white blood cells are discarded. 
 
3 PRP is centrifuged at 800 x g for 10 minutes. The supernatant is 
removed and the platelet pellet is gently resuspended in 1 ml of CGS. 
This 1 ml is transferred to a fresh tube, avoiding transfer of any 
platelets remaining in clumps. CGS is added to the fresh tube to bring 
the volume up to 5 ml. 
 
4 The platelet suspension is centrifuged at 800 x g for 10 minutes. The 
platelet pellet is washed with CGS as in step 3. 
 
5 After 2 washes with CGS, the pellet is resuspended in the appropriate 
buffer, counted with the Coulter Counter, and diluted to the 
appropriate concentration. 
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Table 3.11 Modified Tyrode’s Buffer (HEPES-Tyrode Buffer) 
 
 
Material 
 
Amount 
 
CaCl2 
 
2 mM 
BSA 
 
0.1% 
NaCl 
 
137 mM 
HEPES 
 
20 mM 
Glucose 
 
5.6 mM 
MgCl2 
 
1 mM 
NaH2PO4 
 
3.3 mM 
KCl 
 
2.7 mM 
pH 7.4 
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minutes and with Sigma TRITC-labeled whole molecule goat-anti-mouse 
antibody, 1:128 in PBS, for 30 minutes at room temperature. After washing with 
PBS, CD9 was stained for 30 min with FITC-labeled CD9 antibody clone ML-13, 
diluted 1:40 in PBS. Platelets were fixed for 30 min with 4% paraformaldehyde in 
PBS and washed 3x with PBS. Coverslips were mounted with Vectashield 
mounting media and edges were sealed with clear nail polish. Samples were 
viewed with the confocal microscope using the 100x objective. Care was taken to 
observe samples using the same settings. 
 
 
3.3.3   Impact of Mutant GPIIb-IIIa 
 
 Platelets from patients with Glanzmann Thrombasthenia, featuring a 
mutant GPIIb-IIIa expressed on the platelet surface, were compared with 
platelets from patients with normal GPIIb-IIIa. Platelets were allowed to spread 
on fibronectin or fibrin-fibronectin, and CD9 and GPIIb-IIIa were immunostained 
as above. Fibronectin and fibrin-fibronectin matrices were selected due to 
fibronectin being a ligand for CD9 as well as GPIIb-IIIa. It is unlikely that platelets 
from patients with Glanzmann Thrombasthenia would be able to adhere or  
spread on fibrinogen or fibrin matrices, as the mutated GPIIb-IIIa would likely not 
be able to bind to these ligands. 
 
 
3.4   Localization of CD9 during Platelet Spreading 
 
 
3.4.1   Platelet-Matrix Contact 
 
 Platelets were allowed to spread as described previously. During viewing 
with the confocal microscope, the upper (apical—facing away from matrix) and 
lower (basal—in contact with matrix) boundaries of the platelet were selected by 
focusing the microscope just above and below the regions providing a focused 
view of the platelet. Usually this resulted in a 2-3 nm selection. The LSM 510 
then provided slices corresponding to the apical, central, and basal sections of 
the platelet, which were analyzed for CD9 and GPIIb-IIIa localization and co-
localization. 
 
 
3.4.2   Platelet-Platelet Contact 
 
 Platelets were allowed to spread on 500 μg/ml fibrinogen for 60 minutes in 
the absence of any Fab molecules to allow maximal spreading. Platelets were 
then fixed with 4.0% paraformaldehyde and permeabilized with 0.4% β-
octylglucopyranoside in PHEM buffer (Table 3.12). CD9 was labeled with FITC- 
labeled anti-CD9 antibody (clone ML-13). Samples were mounted and viewed 
with a Zeiss Laser Scanning Microscope using the 100x objective. 
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Table 3.12 PHEM Buffer 
 
 
Material 
 
Concentration 
 
PIPES 
 
60 mM 
HEPES 
 
25 mM 
EGTA 
 
10 mM 
MgCl2 
 
2 mM 
pH 6.9 
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Areas of platelet-platelet contact and corresponding areas of platelet periphery 
not in contact with adjacent platelets were selected and pixel intensity was 
quantified using the Zeiss LSM510 software. 
 
 
3.4.3   Platelet Spreading Structures 
 
 To observe CD9 localization during the course of platelet spreading, 
platelets were allowed to spread on 500 μg/ml fibrinogen for 5-60 minutes in the 
absence of any Fab molecules. At selected time points, platelets were fixed with 
4% paraformaldehyde and permeabilized with β-octylglucopyranoside in PHEM 
buffer, as described above. 
 
 Platelet F-actin was labeled with TRITC-Phalloidin. CD9 was labeled with 
FITC-labeled anti-CD9 antibody (clone ML-13). Samples were mounted and 
viewed with a Zeiss Laser Scanning Microscope using the 100x objective. Care 
was taken to visualize images using the same settings (See also Fig 2.1). 
 
 
3.5   Generation and Purification of mAb7 Fab (mFab7) Fragments 
 
 
3.5.1   Generation of mAb7 
 
mAb7 was obtained from mouse ascites, purified using an Affi-gel Protein 
A column, and dialyzed into PBS. Antibody concentration was assessed using an 
Ultrospec 1000 UV/Visible Spectrophotometer (Pharmacia Biotech) and purity 
confirmed with both nonreducing and reducing SDS-PAGE. 
 
 
3.5.2   Generation of mFab7 
 
Papain digestion of mAb7 and Fab purification was carried out using 
Immunopure® Fab Preparation Kit (Pierce, Rockford, IL) (Fig 3.2). Briefly, mAb7 
was incubated with immobilized papain for five hours in a 37º shaking waterbath. 
The resulting digest was added to a Protein A column, allowing separation of Fab 
fragments from Fc fragments and uncleaved, full-length antibody. The purified 
Fab underwent buffer exchange into phosphate-buffered saline (PBS), pH 7.4, 
using Zeba™ Desalt Spin Columns (Pierce, Rockford, IL). Protein concentration 
was determined as above. 
 
 
3.5.3   Determination of Purity and Function of mFab7 
 
 3.5.3.1   Flow Cytometry.  Binding ability of mFab7 was assessed by flow 
cytometry. Blood was collected by venipuncture through a 21-gauge butterfly  
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Figure 3.2 Antibody Cleavage and Purification of Fab Fragment 
The antibody mAb7 was cleaved by papain, resulting in an Fc and 2 Fab 
fragments. The resulting digest was poured through a Protein A column, which 
bound to Fc fragments and any undigested mAb7. Fab fragments (mFab7), 
which did not interact with Protein A, pass through and are collected.
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needle into 0.1 M buffered citrate. Samples, per established methods, [White 
1999] were centrifuged at 135 x g for 15 minutes to obtain platelet-rich plasma 
(PRP). The remaining blood was centrifuged at 2500 x g for 15 minutes to obtain 
platelet-poor plasma (PPP). Platelet counts were performed using a Beckman 
Coulter Z2 Particle Count and Size Analyzer (Beckman Coulter, Miami, FL), and 
PRP was diluted with autologous PPP to adjust the platelet count to 2.5 x 108 
platelets/mL. Increasing concentrations of nonspecific Fab, mAb7 whole 
molecule, or mFab7 were added to the adjusted PRP and incubated at 37° C for 
30 minutes. FITC-conjugated goat-anti-mouse Fab was added and samples were 
incubated at room temperature for ten minutes. Fluorescence levels were 
measured using a BD FASCalibur flow cytometer with Cell Quest Pro software 
(Becton Dickinson, Mountain View, CA) (see Fig 3.1). 
 
 Purity of mFab7 samples were also confirmed via flow cytometry.  PRP 
was prepared as above, and incubated with saturating amounts of mAb7 or  
mFab7, or corresponding amounts of nonspecific IgG or IgG-Fab at 37° C for 30 
minutes. FITC-labeled goat anti-mouse Fc was incubated at room temperature  
for ten minutes to verify the absence of Fc fragments or intact antibody in the 
mFab7 preparation. Fluorescence levels were measured as above. 
 
 3.5.3.2   SDS-PAGE. 50 μg of mFab7, mAb7, mIgG, and nonspecific 
mIgG-Fab were run on both nonreducing and reducing 12% SDS-PAGE to 
determine purity of mAb7 and mFab7. Gels were evaluated for bands indicating 
the presence of intact antibody by Coomassie blue staining. An unknown protein 
of 60 kDa was verified by mass spectrometry to be murine albumin.  
 
 3.5.3.3   Platelet Aggregation. To evaluate the ability of antibodies to 
induce platelet aggregation, mAb7 (up to 20 μg/ml) or mFab7 (up to 100 μg/ml) 
were added to stirring suspensions of platelets and aggregation response was 
monitored for 15 minutes (Fig 3.3).  
 
Aggregations were also performed using up to 100 μg/ml mFab7 without 
inducing aggregation even after 15 minutes, while mAb7 concentrations > 0.2 
μg/ml induced an aggregation response, confirming that mFab7 was functionally 
greater than 98% pure. 
 
 To further ensure that the Fc receptor was not participating in the 
enhanced aggregatory response, mFab7 and control Fab were pre-incubated 
with a goat F(ab)’2 anti-mouse-Fc before adding to platelets, at a rate of 10 
F(ab)’2 per possible intact mAb7, as calculated above.  
 
 
3.6   CD9 Perturbation 
 
Unless otherwise indicated, CD9 perturbation was carried out by pre-
incubating platelets with 20 μg/ml mFab7 for 15 minutes at room temperature  
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Figure 3.3 Light Transmission Aggregometry 
Upon addition of agonist, formation of platelet aggregates is measured by 
increased light transmission and tracings are recorded on a light transmission 
aggregometer.
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prior to carrying out the experiment. 20 μg/ml nonspecific murine Fab was used 
as a control. The control Fab was isotype-matched to mFab7 and both Fab 
products were handled identically in all experiments. 
  
 
3.6.1   Platelet Spreading 
  
 Fibrin-coated coverslips and fibrin-fibronectin matrix-coated coverslips 
were prepared as previously described [Corbett, 1996]. Additionally, coverslips 
were covered with 500 μg/ml fibrinogen or 50 μg/ml plasma fibronectin overnight.  
ACD-anticoagulated blood was washed twice with CGS (0.01 M sodium citrate, 
0.03 M dextrose, 0.12 M NaCl), pH 6.5, and resuspended in a modified Tyrode’s 
buffer (2 mM CaCl2, 0.1% bovine serum albumin, 137 mM NaCl, 02 mM HEPES, 
5.6 mM glucose, 1mM MgCl2, 2.7 mM KCl, 3.3 mM NaH2PO4), pH 7.4, at 2x10
7 
platelets/ml. Platelets were incubated with 20 μg/ml mFab7 or nonspecific control 
Fab and allowed to adhere and spread on coverslips for 30 minutes. 
 
 Nonadherent platelets were removed by washing with Tyrode’s buffer, and 
adherent platelets were fixed with 4.0% paraformaldehyde for 30 minutes. 
Platelets were permeabilized with 0.4% -ocytlglucopyranoside in PHEM buffer 
(60 mM PIPES [piperazine-N,N’-bis (2-ethane sulfonic acid)], 25 mM HEPES, 10 
mM EGTA, 2mM MgCl2), pH 6.9, for 5 minutes. Platelet F-actin was labeled with 
TRITC-labeled phalloidin and CD9 was labeled with FITC-labeled anti-Fab 
antibody. Coverslips were mounted onto slides with Vectashield Mounting Media 
and edges were sealed with clear nail polish. Samples were visualized with a 
Zeiss laser scanning microscope (LSM 510) using the 100x objective. Care was 
taken to visualize samples using the same settings. 
 
 To quantitate pixel intensity, areas of platelet-platelet contact or 
corresponding areas of the platelet periphery were highlighted and pixel intensity 
(pixels per μm) was quantitated by the LSM 510 software. 
 
 
3.6.2   Platelet Aggregation and Disaggregation 
 
 Platelet aggregation was measured by light transmission in a dual-channel 
lumiaggregometer (Payton Scientific, Buffalo, NY) (See Fig 3.3). PRP was 
preincubated with 20 μg/ml mFab7 or control Fab for 15 minutes at room 
temperature. Agonist concentration was calculated as follows: ADP—the highest 
concentration that would give a biphasic response in the absence of any Fabs (2-
3 μM); Collagen—the concentration that would give a 50% response in the 
absence of Fabs (0.3-1 μg/ml); TRAP—the lowest concentration that would give 
a sustained response in the absence of Fabs (5-12 μM). Low concentrations of 
agonist were chosen as this was the expected range to see an impact of CD9. 
Following preincubation with mFab7 or control Fab, the agonist was added to the 
stirring suspension of platelets, and aggregation response was recorded for 15 
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minutes. The maximum aggregation response was determined for each donor, 
typically at 2.5 minutes after agonist addition.  
 
 Percent platelets aggregation (%PA) was calculated at 5, 10, and 15 
minutes after agonist addition.  To assess platelet disaggregation, 4000 nM 
eptifibatide was added to the platelet aggregates 2.5 min after agonist addition 
and percent platelet disaggregation (%PD) was calculated 5, 10, and 15 minutes 
after antagonist addition (Fig 3.4).  
 
 The following were used to calculate %PA and %PD: 
 
%PA = 
(number of chart divisions on the aggregometer tracing from baseline to 
aggregation response at given time point)/ 
(total number of chart divisions representing 0% [PRP] to 100% aggregation 
[PPP]) 
x 100; 
 
%PD =  
(%PAmax-%PAtime point)/(%PAmax) 
 
 
3.6.3   Platelet Activation 
 
 PRP in citrate was prepared as described above, at 2.5x108 platelets/ml, 
and preincubated with 20 μg/ml mFab7 or control Fab. Selected platelet samples 
were activated with 2 μM ADP or 5 μM TRAP and incubated at room temperature 
for 40 minutes. PE-labeled anti-P-selectin, anti-CD63, or nonspecific mIgG 
antibodies were added to evaluate expression of P-selectin, a marker of alpha 
granule release, and CD63, a marker of lysosomal release, indicating platelet 
degranulation. Platelet fluorescence data, indicating surface protein expression, 
were acquired using a BD FASCalibur flow cytometer with Cell Quest Pro 
Software (Becton Dickinson, Mountain View, CA).  
 
 
3.6.4   Fibrinogen Binding 
 
 Whole blood was drawn into buffered citrate and PRP was prepared by 
centrifugation at 135 x g for 15 minutes and supernatant discarded. Pelleted 
platelets were resuspended in Tyrode’s buffer (138 mM NaCl, 2.9 mM KCl, 12 
mM NaHCO3, 0.4 mM MgCl2, 5.5 mM Dextrose, 0.36 mM NaH2PO4, 1.8 mM 
CaCl2, pH 7.4) at 2.5x10
8 platelets/ml. 100 μl of platelets were incubated with 20 
μg/ml mFab7 or control Fab. Platelets were incubated with 20 μM ADP or saline 
control for 30 minutes at 37°C to allow binding of plasma fibrinogen. Anti-
fibrinogen FITC antibody was added and mixed and data were acquired using a 
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Figure 3.4 Eptifibatide-Induced Platelet Disaggregation 
A, A platelet thrombus is maintained by fibrinogen binding and crosslinking 
GPIIb-IIIa on adjacent platelets. B, Eptifibatide, a small peptide, interacts with 
GPIIb-IIIa and competitively inhibits fibrinogen binding, resulting in platlelet 
disaggregation. The GPIIb-IIIa antagonists abciximab and tirofiban work 
similarl.y.
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BD FASCalibur flow cytometer with Cell Quest Pro software (Becton Dickinson, 
Mountain View, CA).  
 
 
3.6.5   Cytoskeletal Incorporation 
 
 Triton X-100-insoluble cytoskeletons of control and ADP-activated 
platelets in plasma, pretreated with 20 μg/ml mFab7 or 20 μg/ml control Fab, 
were prepared according to the method of Kouns et al [Kouns WC, 1991]. Briefly, 
PRP in citrate were prepared at 3x108 platelets/mL. After pretreatment with Fab, 
2 μM ADP was added to stirring platelet suspension at 37°C. After five minutes,  
samples were rapidly removed and lysed with ice-cold 2% Triton lysis buffer (100  
mM Tris-HCl, 10 mM EGTA, 2% Triton X-100, 2 mM 2-mercaptoethanol, and 
protease inhibitor cocktail tablet; Table 3.13) and lysates were kept on ice.  
 
 Platelet lysates were centrifuged at 4°C at 15,600 x g to isolate the platelet 
core cytoskeleton. The resulting samples were denatured and electrophoresed 
on a 5-20% SDS-polyacrylamide exponential gradient gel overnight. Proteins 
were visualized by staining with Coomassie Blue. Densitometry was performed 
by photocopying each gel, and carefully removing and weighing each band with a 
Sartorius Research quantitative electric balance (Sartorius Research, 
Goettingen, Germany). 
 
 
3.6.6   Akt Phosphorylation 
 
 3.6.6.1   During Platelet Aggregation.  PRP was prepared from whole 
blood and adjusted to 3x108 platelets/ml with PPP. Samples were pretreated with 
saline, control Fab, or mFab7 for 15 minutes at room temperature, then 
monitored with a lumiaggregometer for five minutes upon addition of 2 μM ADP 
or saline. Samples were then centrifuged, and pellets were collected, denatured, 
and subjected to electrophoresis on a 5-20% gradient SDS-PAGE. Proteins were 
transferred to a PVDF membrane, blocked with 5% BSA in TBS-Tween, and 
incubated with an anti-phospho-Akt antibody overnight on a rocker at 4ºC. The 
primary antibody was labeled with a secondary donkey anti-rabbit-HRP antibody 
for 60 minutes in the presence of 5% BSA in TBS-Tween. Membranes were 
developed using the ECL-PLUS kit and stored in PBS at 4ºC until continuing with 
stripping. To strip, membranes were completely submerged in Restore Western 
Blot Stripping Buffer and agitated for 15 minutes at 37ºC. After washing with 
TBS-Tween, western blotting was continued with an anti-Akt (total) antibody. 
Alternatively, the antibody 4G10 was used in place of anti-phospho-Akt antibody, 
to measure total protein tyrosine phosphorylation. 
 
 3.6.6.2   Without Stirring or Aggregation. PRP was prepared from 
whole blood and adjusted to 3x108 platelets/ml with PPP. 500 μl samples were 
treated with saline, control Fab, or mFab7 in eppendorf tubes for 15 minutes at  
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Table 3.13 Cytoskeletal Extraction Buffers, pH 7.4 
 
 
Reagent 
 
2% Triton X-100 
Extraction Buffer 
 
 
Triton-free Wash Buffer 
Tris-HCl 100 mM 100 mM 
 
EGTA 
 
10 mM 
 
10 mM 
 
Triton X-100 
 
2% 
 
---- 
 
2-mercaptoethanol 
 
2 mM 
 
2 mM 
 
Protease Inhibitor Tablet 
 
1 per 10 ml 
 
1 per 10 ml 
53 
room temperature, then treated with saline or 2 μM ADP. After addition of each 
treatment, the suspension was carefully and slowly brought up and down twice in 
a pipette to gently mix. After a five minute incubation, the samples were 
centrifuged in a pre-cooled microcentrifuge and pellets were washed twice with 
ice-cold saline.  
 
 Samples were denatured with reducing sample buffer and 
electrophoresed on a 5-20% gradient SDS-PAGE. Samples were transferred to a 
PVDF membrane, which was incubated overnight on a rocker at 4ºC with anti-
phospho-Akt antibody. After generous washing with TBS-Tween, Akt was labeled 
with donkey anti-rabbit HRP, and 4G10 was labeled with goat anti-mouse HRP. 
Membranes were developed with ECL-PLUS kit and stored in PBS until 
continuing with stripping. To strip, membranes were completely submerged in 
Restore Western Blot Stripping Buffer and agitated for 15 minutes at 37ºC. 
After washing with TBS-Tween, western blotting was continued with an anti-Akt 
(total) antibody. 
 
 
3.6.7   Tetraspanin Web Organization 
 
 Whole  blood was obtained by venipuncture using ACD as an 
anticoagulant. Platelets were washed twice with CGS and resuspended at 
250,000/mm3 in ACD. After pretreatment with 20 μg/ml mFab7 or control Fab for 
15 minutes at room temperature, platelets were activated with 2 μM ADP or 
allowed to remain in a resting state. Samples were removed for flow cytometric 
evaluation of CD63 and P-selectin on the platelet surface to verify platelet 
activation. Platelet samples were then resuspended in 1% Brij-98 lysis buffer and 
lysed overnight on a rocker at 4ºC. Samples were clarified by centrifugation at 
18,300 x g for 10 minutes at 4ºC and the pellet was discarded. Protein 
concentration was detected using the Biorad Detergent-Compatible Assay kit and 
protein concentration adjusted to 1.5 mg/ml.  
 
 Samples were precleared with Protein A beads, centrifuged, and the 
supernatant transferred to a clean tube. Samples were then incubated for one 
hour at 4ºC with mIgG as a control or with 10E5, an antibody that binds the 
GPIIb-IIIa complex regardless of activation conformation.  Samples were then 
incubated with Protein A beads overnight on a rocker at 4ºC.  
 
 Immunoprecipitation complexes were separated on a 5-20% reducing 
SDS-PAGE and transferred to a PVDF membrane. After the transfer, the 
membrane was cropped from 15 kDa to 35 kDa to probe for CD9 (mAb7); from 
35 kDa to 75 kDa to probe for CD63 (BD anti-CD63); and from 75 kDa to above 
160 kDa to probe for GPIIb-IIIa (C3). Probing occurred overnight at 4ºC. Primary 
antibodies were then labeled with HRP-conjugated Sheep anti-mouse antibody in 
TBS-Tween + 5% nonfat dry milk and images developed with ECL-PLUS kit. 
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3.6.8   Clot Retraction 
 
 Whole blood was obtained by venipuncture using 0.1 M buffered citrate as 
an anticoagulant. PRP was obtained and diluted with PPP to obtain platelets at 
either 250,000/mm3 or 100,000/ mm3. After 15 minutes incubation in eppendorf 
tubes with 20 μg/ml mFab7, 20 μg/ml control Fab, corresponding volume of 
saline, or 20 μg/ml D3 (as a positive control) samples were transferred to 12 x 75 
glass tubes. CaCl2 was added to each tube, samples were mixed by flicking, and 
each tube was capped and incubated in a 37 ° C waterbath. Tubes were 
observed every 15 minutes until retraction was complete. 
 
 
3.7   Statistical Significance 
 
 Values are reported as mean ± standard deviation as calculated by 
Microsoft Excel (Microsoft Corporation, Seattle, WA). T-tests were performed 
using Microsoft Excel. Results of cytoskeletal incorporation and aggregation with 
recombinant proteins were evaluated using ANOVA (Boneferroni test) with 
Sigma stat software. 
 
 Results are expressed as percentages ± standard deviation. p value of 
≤0.05 was accepted as statistically significant.  
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CHAPTER 4   RESULTS 
 
   
4.1   Tetraspanin Expression on Resting and Activated Platelets 
 
The surface expression levels of CD9, the tetraspanins CD63 and CD151, 
and the tetraspanin-associated proteins GPIb and GPIIb-IIIa (integrin αIIbβ3) was 
evaluated in platelets that were either allowed to remain resting or were activated 
with 10 μM ADP or 5 μM TRAP (Fig 4.1A). Although TRAP is a more potent 
agonist than ADP, these concentrations should induce platelet activation, 
including granule release. 
 
Although CD9 has been characterized as a member of alpha granules 
(Brisson 1997, Cramer 1994), the surface expression of CD9 in resting platelets 
(mean fluorescence intensity (MFI) = 183.2 ± 28.7) versus ADP- (236.4 ± 25.8) or 
TRAP-activated (229.0 ± 30.3) platelets was not statistically significantly different. 
The lack of statistical significance may be due to the wide range of CD9 
expression among individual donors, as each donor showed an increase in CD9 
surface expression upon activation, particularly with ADP (Fig 4.1B). 
 
As expected, resting platelets did not express CD63 (MFI = 8.2 ± 1.3, 
compared to background control mIgG (MFI = 8.0 ± 1.0). CD63 expression was 
detected upon ADP activation (16.5 ± 3.2) and TRAP activation (27.7 ± 5.9). The 
increase in CD63 expression was statistically significant in activated vs. resting 
platelets (p<0.05), but not between ADP and TRAP activation (p>0.05). 
 
CD151 was detected on the surface of resting platelets (MFI = 24.6 ± 2.5), 
and was statistically significantly increased by ADP activation (MFI = 42.4 ± 2.8, 
p ≤ 0.01 compared to resting) or by TRAP activation (MFI = 46.2 ± 3.4, p ≤ 0.01). 
 
GPIIb-IIIa surface expression was detected by the antibody 10E5. This 
antibody binds to the GPIIb-IIIa complex, and has an equal affinity for both the 
active and inactive conformation of GPIIb-IIIa, so integrin activation following 
platelet activation will not alter detection of surface expression. GPIIb-IIIa was 
detected on the surface of resting platelets (MFI = 129.6 ± 11.0), and was 
statistically significantly increased by activation by ADP (MFI = 218.5 ± 15.8, 
p<0.01) or TRAP (MFI = 214.4 ± 13.8, p<0.01). 
 
GPIb, part of the GPIb-IX-V complex, was also detected on the surface of 
resting platelets (MFI = 84.5 ± 4.5). Its level was increased to 117.2 ± 7.7 by ADP 
activation and to 103.9 ± 7.3 by TRAP activation. The difference between resting 
and ADP-activated platelets was statistically significant (p<0.01), but the 
difference between resting and TRAP-activated platelets was not statistically 
significant (p>0.05). This slight decrease following TRAP activation, compared to 
ADP activation, may be due to this receptor shedding its alpha subunit following 
potent activation (Bergmeier 2004). 
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Figure 4.1 Expression of Tetraspanins on the Platelet Surface 
A, Platelet surface expression of CD9, CD151, CD63, GPIIb-IIIa, and GPIb under 
resting conditions or activated with ADP or TRAP, as measured by flow 
cytometry. mIgG provides a negative background control. CD9 does not show a 
statistically significant increase in expression upon platelet activation. CD151, 
CD63, and GPIIb-IIIa display a statistically significant increase in expression 
upon platelet activation, whether by ADP or TRAP. GPIb displays an increase in 
surface expression upon mild activation by ADP, but not a statistically significant 
increase upon stronger activation by TRAP. B, mAb7 binding to resting or 
activated platelets of individual donors. *, p<0.05; **, p<0.001; n=5. 
** 
** * ** 
** 
** 
** 
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4.2   Association of CD9 and GPIIb-IIIa in Resting and Activated Platelets 
 
 
4.2.1   Co-Immunoprecipitations 
 
Immunoprecipitations were performed using 1% CHAPS, a mild detergent 
which does not disrupt the integrity of the tetraspanin web. The platelet lysate 
was either immunoprecipitated with mIgG, a nonspecific antibody; mAb7, a CD9 
EC2 antibody; or D3, a GPIIb-IIIa antibody (Fig 4.2). D3 was used in the 
presence or absence of eptifibatide to evaluate the effect of receptor occupancy 
on CD9-GPIIb-IIIa interactions. 
 
After protein separation by SDS-PAGE, a denaturing polyacrylamide gel 
electrophoresis, immunoprecipitates were probed for CD9 or GPIIb (a component 
of GPIIb-IIIa). D3 was found to immunoprecipitate GPIIb, with no difference upon 
inclusion of eptifibatide. D3 also co-immunoprecipitated a portion of CD9, with no 
difference upon inclusion of eptifibatide. Conversely, mAb7 was able to 
immunoprecipitate CD9 and co-immunoprecipitate a portion of GPIIb. The 
negative control, mIgG, was not able to immunoprecipitate either protein, 
confirming antibody specificity. 
 
These results indicate that a portion of CD9 and GPIIb-IIIa associate with 
each other in the membrane, and that this interaction is maintained with 1% 
CHAPS. Integrin binding to eptifibatide does not appear to alter the association 
between CD9 and GPIIb-IIIa, suggesting that the association between CD9 and 
GPIIb-IIIa may be controlled by another mechanism besides ligand binding to the 
integrin. 
 
 
4.2.2   Confocal Analysis 
 
 Platelets were allowed to spread on four matrix substrates: FG, FN, Fb-
FN, or Fb (Fig 4.3). All of these matrix proteins are ligands for GPIIb-IIIa, and FN 
is additionally a ligand of CD9. After 60 minutes, most adherent platelets were 
fully spread, although there were some platelets just extending filopodia or 
lamellipodia. At this concentration, some platelets did not contact other platelets, 
while other platelets were in direct physical contact with adjacent platelets. 
 
 On all matrices, CD9 was most intense at platelet-platelet contacts. 
Additionally, CD9 was pronounced at the platelet periphery, within the extended 
filopodia and lamellipodia, and centralized at discrete points in the platelet body 
(potentially where granules were clustered).  
 
 The matrices displayed some modest differences in CD9 distribution.  
CD9 localization on fibrin or fibrin-FN was more diffuse, with increased signal 
across the entire surface of the platelet compared to FG or FN. 
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Figure 4.2 Co-Immunoprecipitation of CD9 and GPIIb-IIIa 
A, GPIIb is detected in samples immunoprecipitated with the CD9 antibody 
mAb7, as well as the GPIIb-IIIa LIBS antibody D3 in the presence or absence of 
4000 nM eptifibatide. B, CD9 is deteted in samples immunoprecipitated with 
mAb7, and a fraction of C9 is co-immunoprecipitated with D3. Co-
immunoprecipitation is not altered by the presence of 4000nM eptifibatide. mIgG 
is not able to precipitate GPIIb or CD9.
I.P.:    lysate      mIgG    mAb7    D3+Eptif.   D3 
I.P.:  lysate       mIgG       mAb7     D3+Eptif.  D3 
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Figure 4.3 Localization of CD9 and GPIIb-IIIa in Spread Platelets 
CD9 staining by ML13-FITC is similar in platelets spread on either FG or FN. 
CD9 can be found across the entire platelet surface, but is most intense at the 
platelet periphery or in filopodia. There is also an increased level of CD9 at 
platelet-platelet contact sites. GPIIb-IIIa staining by D3-TRITC on both matries is 
concentrated on the periphery of the spread platelets. Staining is also present in 
platelet centers. Colocalization between CD9 and GPIIb-IIIa is found at the 
platelet periphery. Colocalization is also found at platelet-platelet contact sites in 
platelets spread on FG. In platelets spread on fibrin, CD9 localization is diffuse 
across the entire platelet surface. In platelets spread on fibrin, CD9 localization is 
diffuse across the entire platelet surface. In platelets spread on fibrin-FN, the 
CD9 localizaiton appears as an intermediate between platelets spread on fibrin. 
On both matrices, colocalization is found at the platelet-platelet contact sites.
FG 
FN 
     CD9                  GPIIb-IIIa        Merge 
Fibrin-
FN 
Fibrin 
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 GPIIb-IIIa also tended to be most intense at the platelet periphery and 
platelet centers. GPIIb-IIIa was most diffuse in platelets spread on fibrin. There 
was extensive co-localization between CD9 and GPIIb-IIIa in spread platelets on 
all matrices. Co-localization was most pronounced at the platelet periphery and 
at platelet-platelet contacts. This suggests that CD9 plays an important role in 
modulating GPIIb-IIIa adhesive functions at platelet-platelet contacts and in 
platelet spreading. CD9 may alter the conformation of GPIIb-IIIa at these areas, 
or may be modulating the presentation of ligand to integrin. 
 
 
4.2.3   Impact of Mutant GPIIb-IIIa 
 
 Platelets from patients with Glanzmann Thrombasthenia, expressing  
mutant GPIIb-IIIa on the surface that is incapable of binding ligand, were able to 
bind and spread on fibronectin and fibrin-fibronectin (Fig 4.4). The platelet 
adhesion and spreading ability may be due to other platelet integrins, to CD9, or 
to a possible unaffected ligand binding site on GPIIb-IIIa. Interestingly, a subset 
of the platelets expressing the mutant GPIIb-IIIa exhibited abnormal platelet 
spreading on both matrices—they spread over a larger surface area on fibrin, 
and over a smaller surface area on fibrin-fibronectin, compared to normal 
controls.  
 
 Although co-localization analysis is difficult to perform due to the 
diminished GPIIb-IIIa staining, it appears that the expressed GPIIb-IIIa exhibits 
localization and CD9 colocalization similar to normal platelets. 
 
 In the platelets expressing mutant GPIIb-IIIa, flow cytometric analysis 
demonstrated that CD9 expression was increased (data not shown). This could 
be due to attempted compensation, as CD9 is believed to be a receptor for 
fibronectin and could attenuate the impact of mutated GPIIb-IIIa. However, it is 
also possible that the mutation of GPIIb-IIIa alters the CD9-GPIIb-IIIa association 
to such an extent that there is better access for antibody binding. 
 
 
4.3   Localization of CD9 during Platelet Spreading 
 
 
4.3.1   Platelet-Matrix Contact 
 
 Slices of spread platelets were viewed independently of other slices above 
or below the desired plane using the confocal microscope (Fig 4.5). Platelets 
were sliced into three sections: the basal section included the segment of the 
platelet in contact with the matrix; the apical section was the upper third of the 
platelet facing away from the matrix; and the central section comprised the 
portion of the platelet between these two sections. 
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Figure 4.4 CD9 Localization in Glanzmann Thrombasthenia 
A, Comparison of normal and GT platelets spread on FN. B, Comparison of 
normal and GT platelets spread on Fb-FN. Green, CD9 ; Red, GPIIb-IIIa ; Yellow, 
merge. Note that GPIIb-IIIa mutation does not alter platelet adhesion nor the 
colocalization etween CD9 and GPIIb-IIIa ; however, extent of platelet spreading 
is altered, with platelets spreading more on Fb and less on Fb-FN compared to 
normal controls.
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Figure 4.5 Analysis of CD9 Localization in Platelet Sections with or 
without Matrix Contact 
GPIIb-IIIa (D3-TRITC, red) is localized in the basal portion of the platelet (in 
contact with the matrix). Much lower GPIIb-IIIa levels are observed in the apical 
sections of the platelet. CD9 (ML13-FITC, green) is found in the apical and 
central sections of the platelet, but only a low level of expression is observed in 
contact with matrix. Co-localization (yellow) between CD9 and GPIIb-IIIa is found 
mainly at the platelet-platelet contact sites. There is only a low level of CD9 and 
GPIIb-IIIa colocalization at platelet-matrix contact sites on the basal portion of the 
platelet. Additionally, only a low level of colocalization is observed at the apical 
sections of the platelets.
FG                    FN                Fibrin                  Fibrin-FN 
 
 
Basal 
Central 
Apical 
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 GPIIb-IIIa expression was found to be intense in the basal section, where 
platelets were in contact with the matrix. GPIIb-IIIa was also found at regions of 
platelet-platelet contact in the basal and central sections. Surprisingly, there was 
very little CD9 expression observed in the basal section of the platelets on any of 
the matrices. This indicates that CD9 does not likely have an important role in 
direct  adhesion to the matrix—even to fibronectin, a known ligand—or to 
modulating GPIIb-IIIa adhesion to the matrix. However, the expression of CD9 in 
spreading structures such as filopodia and lamellipodia suggests a role for CD9 
in platelet spreading events. CD9 expression was intense in the central region of 
the platelet, where it was strongly colocalized with GPIIb-IIIa, particularly at 
platelet-platelet contact sites. This further indicates a likely involvement of CD9 in 
modulating the role of GPIIb-IIIa in platelet-platelet interaction and thrombus 
stability.  
 
 Only low levels of CD9 or GPIIb-IIIa were observed in the apical sections 
of platelets. This is not unusual, as both proteins would be expected to be 
localized to sections of the platelet membrane involved in contact with platelets 
or matrix. 
 
 
4.3.2   Platelet-Platelet Contact 
 
When platelet spreading resulted in platelet-platelet contact, CD9 staining 
was greatly intensified at these contact points (pixel intensity = 141.5 ± 8.9) 
compared to the platelet periphery not involved in platelet-platelet contact (pixel 
intensity = 32.7 ± 16.2) (Fig 4.6). It is evident that CD9 is being actively localized 
into areas of platelet-platelet contact, and not merely an additive effect, as the 
intensity at platelet-platelet contact is more than double the intensity at non-
contact periphery. 
 
 
4.3.3   Platelet Spreading Structures 
 
 The localization of CD9 was initially characterized in platelets throughout 
the stages of adhesion and spreading on fibrinogen, as well as its colocalization 
with F-actin, using confocal microscopy (Fig 4.7). Immediately upon adhesion to 
fibrinogen, platelets developed a rounded shape, with CD9 distributed throughout 
the entire platelet surface. CD9 was colocalized with F-actin as evidenced by the 
yellow merge signal. As the platelet began extending filopodia and lamellipodia, 
CD9 was increasingly localized to these extensions. Co-localization with F-actin 
was still observed, although the degree of co-localization was decreased as 
platelet spreading proceeded. As the platelet progressed to a fully spread 
morphology, CD9 was distributed evenly across the platelet membrane; however, 
after 60 minutes, a large portion of CD9 localized in punctate clusters at the 
leading edge of the platelet.  Co-localization of CD9 and F-actin was no longer 
evident.  
64 
A 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
B 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.6 Localization of CD9 at Platelet-Platelet Contacts 
A, CD9 staining is intensified at areas of contact between spread platelets (red 
arrowheads). B, Quantitation of pixel intensity at platelet-platelet contacts vs. the 
platelet periphery not involved in platelet-platelet contacts. These data indicate 
that CD9 is actively localized at platelet-platelet contacts, and that the 
observation is not due to the additive effect of multiple platelet membranes in 
contact. **, p<0.01. n=4. 
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Figure 4.7 Localization of CD9 and Actin during Platelet Spreading 
Washed platelets in progressive stages of platelet spreading. In newly adherent, 
round platelets, CD9 (ML13-FITC) covers the platelet surface.  There is a high 
level of colocalization with F-actin (Phalloidin-TRITC).  As the platelet extends 
filopodia and lamellipodia, CD9 is highly expressed in these areas.  The level of 
CD9 and actin co-localization appears to diminish as the platelet proceeds 
through the spreading process.  In a nascent, spread platelet, the CD9 is found 
across the platelet membrane but is most strongly expressed at the platelet 
periphery.  As platelets are allowed to spread for 60 minutes, CD9 localizes to 
discrete, punctuate areas on the platelet periphery, although there is still CD9 
localized across the entire platelet surface. n=4. 
Round        Filopodia     Lamellipodia      Spread          Punctate 
 Merge 
CD9 
   F-actin 
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4.4   Generation and Purification of mAb7 Fab (mFab7) Fragments 
 
 To evaluate the role of CD9 independently from the platelet FcRII 
receptor, Fab fragments were created from the monoclonal antibody mAb7, an 
antibody with a high affinity for CD9 EC2. This antibody was chosen due to its 
functional effects in smooth muscle cells (unpublished data) as well as its 
functional effects in CHO cells transfected with human GPIIb-IIIa (Cook 1999). 
 
Upon cleavage with papain and passage through a Protein A column, the 
isolated Fab fragments, henceforth designated mFab7, along with intact mAb7 
and control mIgG and control mIgG Fab fragments, were electrophoresed 
reduced and nonreduced through SDS 5-20% polyacrylamide gradient gels. 
Protein staining by Gelcode Blue showed a homogeneous preparation with no 
detectable intact mAb7 even with > 50 μg Fab protein loaded onto the gel (Fig 
4.8A). The contaminant band of approximately 60 kDa in mAb7 and mFab7 lanes 
was excised and subjected to mass spectrometry. This protein was identified as 
murine albumin (data not shown). 
 
As intact mAb7 can induce platelet aggregation, aggregation tracings were 
recorded with mAb7 and mFab7 to verify that mFab7 was purified, without any 
traces of intact antibody. Aggregations performed using up to 100 μg/ml mFab7 
did not induce aggregation even after 15 minutes, while mAb7 concentrations > 
0.2 μg/ml induced an aggregation response (Fig 4.8B). Therefore, from a 
functional perspective, the mFab7 was virtually free of intact, functional mAb7. 
 
A FITC-labeled, goat anti-mouse-Fab antibody was used to verify binding 
competency of mFab7 under flow cytometry. Mean fluorescence intensity (MFI), 
measuring binding of anti-Fab to mAb7 and mFab7, was 92.45 and 112.84, 
respectively, indicating Fab7 binding was similar to that of the intact mAb7 
antibody (Fig 4.8C). When a FITC-labeled goat anti-mouse-Fc antibody was 
used, the MFI for the mAb7 sample was 108.58 as expected, while the MFI of the 
mFab7 sample was reduced to control mouse levels, further indicating that the 
mFab7 sample was free of intact mAb7 (Fig 4.8D). 
 
 
4.5   CD9 Perturbation 
 
 
4.5.1   Platelet Spreading 
 
 Human platelets were pre-incubated with either control isotype-matched 
Fab (control) or mFab7 then allowed to spread on one of four matrices—
fibronectin (FN), fibrin (Fb), Fb-FN cross-linked matrix, or fibrinogen (FG)—all 
four of which are ligands for GPIIb-IIIa, the major platelet integrin, and are  
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Figure 4.8 Purification of mFab7 from mAb7 
A, mAb7 digests on a non-reducing or reducing SDS-PAGE. Lane 1, undigested 
control mIgG; lane 2, control Fab; lane 3 undigested mAb7; lane 4, mFab7; 50 μg 
protein per lane.  B, mAb7 causes platelet aggregation when added to a stirring 
suspension of platelets, but mFab7 does not cause platelet aggregation.  C, Flow 
cytometric analysis indicates mFab7 binding ability on the platelet surface.  D, 
Flow cytometric analysis reveals that an anti-Fc antibody does not bind to 
platelets with mFab7, further indicating purity.  
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Figure 4.8 (continued) 
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exposed to platelets as components of plasma, atherosclerotic plaques, or at 
sites of vascular injury.  
 
Pre-incubation with mFab7 did not appear to alter the localization or 
staining pattern of CD9 or F-actin, but it increased the stage of spreading of 
platelets on all four matrices (Fig 4.9). When platelets on Fb were quantified 
based on stage of spreading, it was found that platelets were in the early stages 
of platelet spreading—either newly adherent or extending filopodia—when they 
were preincubated with control Fab (p<0.05), whereas platelets treated with the 
mFab7 were more likely to be fully spread. Similarly, platelets on FN, Fb-FN, or 
FG were adherent or extending filopodia when pretreated with control Fab 
(p<0.05), but were extending lamellipodia or fully spread when pretreated with 
mFab7.  
 
Interestingly, treatment with mFab7 increased the total number of 
adherent platelets on Fb-FN per frame (p<0.05), but this treatment led to no 
difference in the total number of adherent platelets per frame on the other 
matrices.    
 
Additionally, mFab7 decreased the relative amount of actin co-localizing 
with CD9 on FbFN (62 ± 12% with control Fab vs 30 ± 6% with mFab7) and on 
FG (45 ± 7% with control Fab vs 24 ± 7% with mFab7) (Fig 4.10), but a change 
was not statistically significant on FN or Fb. A decrease in colocalization is likely 
because mFab7 treatment enhances platelet spreading, and a normal decrease 
in CD9-actin colocalization is observed as platelets spread more fully. 
 
 
4.5.2   Platelet Aggregation and Disaggregation 
 
 MFab7 also increased the aggregation of platelets in response to low 
concentrations of ADP (2-3 μM) or collagen (0.6-1.0 μg/ml) (Fig 4.11 and Table 
4.1). In response to threshold ADP, the control sample exhibited a mean maximal 
aggregation of 54.3 ± 5.0%, which then decreased to 43.7 ± 4.7%, 26.7 ± 4.0%, 
and 20.0 ± 2.0% after 5, 10, and 15 minutes, respectively. When mFab7 was 
used, the maximal aggregation is 73.7 ± 7.5%, and the aggregate is more stable, 
with 70.7 ± 12.7%, 64.7 ± 16.3%, and 59.3 ± 15.5% aggregation for 5, 10, or 15 
minutes after addition of agonist. When threshold levels of collagen were used, 
the results were similar: for control-treated platelets, the percent aggregation is 
62.0 ± 10.4%, 60.3 ± 13.3%, 52.0 ± 14.9%, and 44.7 ± 14.1%, respectively, for 
maximal aggregation, and 5, 10, or 15 minutes after addition of agonist. For 
mFab7-treated platelets, this increased to 72.3 ± 3.1%, 72.3 ± 3.1%, 68.0 ± 
2.6%, and 62.3 ± 2.1%, respectively. When platelets were activated by threshold 
levels of Thrombin Receptor Agonist Peptide (TRAP, 5-10 μM), mFab7 did not 
increase the aggregation: 72.3 ± 7.6%, 71.3 ± 8.7%, 65.3 ± 13.6%, and 58.7 ± 
15.3% for control vs. 72.7 ± 9.7%, 71.7 ± 11.7%, 66.7 ± 14.0%, and 61.0 ± 14.9% 
for mFab7 (Fig 4.11C and Table 4.1). 
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Figure 4.9 CD9 Affects Platelet Spreading on Fibronectin (FN), Fibrin (Fb), 
Fibrin-Fibronectin Matrix (Fb-FN), or Fibrinogen (FG) 
A,Quantification of platelets throughout stages of platelet spreading. B, Confocal 
microscopy images show platelets that are incubated with 20 μg/ml mFab7 (right) 
exhibit greater spreading on all matrices than platelets that are incubated with 20 
μg/ml of a nonspecific control Fab. Localization of CD9 does not appear to be 
altered by mFab7 binding. C, Zoom of Merge view from B. *, p<0.05. **, p<0.01. 
n=5. 
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Figure 4.9 (continued)
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Figure 4.9 (continued)
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Figure 4.10 Impact of CD9 Perturbation on Colocalization with F-actin 
CD9 perturbation with mFab7 results in decreased levels of F-actin (as 
measured by TRITC-phalloidin) co-localizing with CD9 (as measured by 
ML13-FITC) in platelet spreading on FbFN and on FG. Perturbation does not 
lead to statistically significant changes in colocalization in platelets spread 
on Fb or on FN. n=5. **, p<0.01.
** 
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Figure 4.11 CD9 Affects Platelet Aggregation 
A, Platelets activated by ADP. Preincubation with mFab7 results in a significant 
increase in percent aggregation at all time points compared to preincubation with 
control Fab.  B, Platelets activated by collagen. Preincubation with mFab7 results 
in a significant increase in percent aggregation at maximum aggregation and at 
10 and 15 minutes after addition of collagen. C, Platelets activated by thrombin 
receptor agonist peptide (TRAP). Preincubation with mFab7 does not alter 
platelet aggregation. max, maximum aggregation after addition of agonist.  
*, p<0.05. **, p<0.01. n=4. 
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Table 4.1. Perturbation of CD9 Affects Percent Platelet Aggregation1 
 
 
Agonist 
 
Fab 
 
Max 
aggregation 
 
 
5 min 
 
10 min 
 
15 min 
ADP mFab7 73.7 ± 7.5 70.7 ± 12.7 64.7 ± 16.3 59.3 ± 15.5 
 control Fab 
 
54.3 ± 5.0 43.7 ± 4.7 26.7 ± 4.0 20.0 ± 2.0 
Collagen mFab7 72.3 ± 3.1 72.3 ± 3.1 68.0 ± 2.6 62.3 ± 2.1 
 control Fab 
 
62.0 ± 10.4 60.3 ± 13.3 52.0 ± 14.9 44.7 ± 14.1 
TRAP mFab7 72.7 ± 9.7 71.7 ± 11.7 66.7 ± 14.0 61.0 ± 14.9 
 control Fab 72.3 ± 7.6 71.3 ± 8.7 65.3 ± 13.6 58.7 ± 15.3 
                                            
1 Percent platelet aggregation, showing the maximum aggregation achieved, and 
percent aggregation at 5, 10, and 15 minutes after addition of agonist, ± standard 
deviation. 
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 Eptifibatide, a GPIIb-IIIa antagonist, is also used in conjunction with these 
agonists to evaluate platelet disaggregation. The addition of eptifibatide to 
platelet aggregates enhances the rate and extent of disaggregation of platelet 
aggregates by displacing bound fibrinogen to the activated GPIIb-IIIa receptor. 
The ability of eptifibatide to increase the rate and extent of platelet 
disaggregation was decreased by treatment with mFab7 with all three agonists 
studied (Fig 4.12 and Table 4.2); however, the effect of eptifibatide was not 
totally blocked. When threshold ADP was the agonist, percent aggregation at 5, 
10, and 15 minutes after addition of eptifibatide was 38.3 ± 2.1%, 23.7 ± 2.5%, 
and 19.3 ± 2.3%, respectively, for control-treated platelets, and 57.3 ± 5.1%, 44.7 
± 6.1%, and 38.7 ± 6.7%, respectively, for mFab7-treated platelets. When 
threshold collagen was the agonist, the percent aggregation for control-treated 
platelets was 31.0 ± 19.1%, 27.0 ± 17.4%, and 24.6 ± 16.7%, respectively, while 
for mFab7-treated platelets it was 62.3 ± 8.1%, 57.0 ± 9.8%, and 53.3 ± 11.2%, 
respectively. mFab7 even exerted an effect on disaggregation when TRAP was 
used as the agonist: percent aggregation was 45 ± 18.1%, 33.7 ± 15.3%, and 
29.0 ± 13.0% with control-treated platelets, and 63.3 ± 1.5%, 51.3 ± 3.1%, and 
46.3 ± 2.1% for mFab7-treated platelets. 
 
Additionally, mFab7 and control Fab were pre-incubated with a goat 
F(ab)’2 anti-mouse-Fc before adding to platelets, at a rate of 10 F(ab)’2 per 
possible intact mAb7, as calculated above. Although the F(ab)’2 slightly 
decreased aggregation, the mFab7 still exhibited increased aggregation and 
thrombus stability compared to the control Fab. 
 
The results from these experiments led to the hypothesis that CD9 may 
indeed serve as a link to integrin activation and its function may serve as a 
tipping point for platelet reactivity. Further examination of GPIIb-IIIa function, 
such as fibrinogen binding, was measured with or without Fab treatments. 
 
 
4.5.3   Platelet Activation 
 
 Platelet activation was assessed by detection of CD63 and P-selectin 
(CD62) via flow cytometric analyses (Fig 4.13). Resting platelets, in the absence 
of agonist, did not have a statistically significant difference in the measurement of 
either CD63 or P-selectin between control- and mFab7-treated platelets. 
However, when platelets were activated by threshold levels of ADP (2 μM), 
mFab7 treatment increased the expression of both CD63 and P-selectin: the MFI 
for control-treated platelets was 33.3 ± 0.2 for P-selectin and 14.1 ± 3.0 for 
CD63, while for mFab7-treated platelets the MFI was increased to 91.1 ± 14.8 for 
P-selectin and 25.6 ± 3.3 for CD63. Interestingly, mFab7 did not increase the 
expression of either protein when platelets were activated with threshold TRAP 
(10 μM). Future studies can be performed to determine the optimal concentration 
of TRAP for mFab7 to amplify the signal. 
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Figure 4.12 CD9 Affects Eptifibatide-Induced Platelet Disaggregation 
4000 nM eptifibatide is added to agonist-activated platelets at the point of 
maximum aggregation (2.5 min after addition of agonist). Incubation with mFab7 
results in more stable aggregates with all agonists tested. A, ADP; B, Collagen; 
C, TRAP. *, p<0.05; **, p<0.01. n=4. 
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Figure 4.12 (continued) 
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Table 4.2. Perturbation of CD9 Affects Eptifibatide-Induced Platelet 
Disaggregation2 
 
 
Agonist 
 
Fab 
 
Max 
aggregation 
 
 
5 min 
 
10 min 
 
15 min 
ADP mFab7 69.4±4.0 57.3±5.1 44.7±6.1 38.7±6.7 
 control Fab 
 
63.3±4.5 38.3±2.1 23.7±2.5 19.3±2.3 
Collagen mFab7 72.7±3.7 62.3±8.1 57.0±9.8 53.3±11.2 
 control Fab 
 
59.3±8.0 31.0±19.1 27.0±17.4 24.6±16.7 
TRAP mFab7 74.7±0.6 63.3±1.5 51.3±3.1 46.3±2.1 
 control Fab 68.7±4.5 45±18.1 33.7±15.3 29.0±13.0 
                                            
2 Percent platelet aggregation, showing the maximum aggregation achieved, and 
percent aggregation at 5, 10, and 15 minutes after addition of eptifibatide, ± 
standard deviation. 
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Figure 4.13 CD9 Affects Platelet Activation  
Pre-incubation with 20 μg/ml mFab7 increases P-selectin (CD62P) and CD63 
expression on platelets activated with 2 μM ADP, compared to platelets pre-
incubated with 20 μg/ml nonspecific control Fab. mFab7 did not affect P-selectin 
or CD63 expression on platelets that were activated with 10 μM TRAP or on 
platelets that were not activated by agonist. **, p<0.01. n=5. 
** 
** 
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4.5.4   Fibrinogen Binding 
 
 In the absence of agonist stimulation, platelets bound a low level of 
fibrinogen, with no difference between control Fab-treated platelets and mFab7-
treated platelets (mean MFI = 48.06 ± 22.3 and 48.13 ±  22.5, respectively) (Fig 
4.14). When platelets were activated without stirring by 2 μM ADP, the binding of 
fibrinogen increased slightly (MFI = 70.13 ± 5.4). The most notable increase in 
fibrinogen binding occurred when platelets treated with mFab7 and activated by 
ADP (MFI = 122.1 ± 15.9). The increase in fibrinogen binding of ADP-activated 
platelets that are treated by mFab7 versus treated by control Fab is significant as 
determined by ANOVA. 
 
 
4.5.5   Cytoskeletal Incorporation 
 
 In order to explore CD9 effects on the integrin-cytoskeleton linkage, core 
cytoskeletons were prepared from mFab7 treated platelets. Platelet samples 
were lysed at five min after addition of agonist. mFab7 increased the 
incorporation of the cytoskeletal proteins actin binding protein (ABP), α-actinin, 
and actin into the core cytoskeleton compared to control-treated platelets 
(Fig 4.15A). Platelets activated by 2 μM ADP, pre-incubated with control Fab or 
without Fab, did not form stable aggregates, and thus the incorporation of these 
proteins was similar to the level of incorporation in resting platelets. Similarly, 
incubation with mFab7 or control Fab in the absence of ADP did not increase 
cytoskeletal protein incorporation. However, when platelets were incubated with 
mFab7 and activated with 2 μM ADP, the incorporation of ABP, α-actinin, and 
actin into the core cytoskeleton increased to levels higher than seen with mFab7 
or ADP alone. The level of incorporation was similar to levels observed when 
platelets were activated with 5 μM ADP, a concentration which allows formation 
of more stable aggregates. The relative density of actin incorporated into the 
platelet cytoskeletons is shown (Fig 4.15B). Statistical significance is designated 
by asterisks. 
 
 
4.5.6   Akt Phosphorylation 
  
 In order to examine possible signaling molecules involved in CD9-
mediated platelet functions, platelets were pretreated with mFab7, control Fab, or 
saline control and stirred in the aggregometer, with or without threshold ADP, for 
5 minutes. Total platelet lysates were separated and transferred to a PVDF 
membrane, which was blotted with the antibody 4G10. This antibody is capable 
of binding to phosphorylated tyrosine residues without preference for a particular 
protein. This resulted in the appearance of several bands, most prominently Akt. 
However, CD9 ligation by mFab7 did not appear to alter the intensity of any of 
the bands (4G10 data not shown). 
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Figure 4.14 CD9 Affects Ligand Binding 
Platelet incubation with mFab7 results in increased fibrinogen binding in the 
presence of ADP as indicated by increased PAC-1 binding. mFab7 does not 
affect fibrinogen binding in resting platelets. **, p<0.01.  n=4.
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Figure 4.15 CD9 Alters the Platelet Core Cytoskeleton 
A, Coomassie-blue-stained reduced gel showing increase in ABP, myosin, -
actinin, and actin in the presence of ADP and mFab7. Lanes: A, total platelet 
lysates, at 50% platelet count compared to other lanes; B, resting platelets; C, 
treated with 2 μM ADP; D, treated with mFab7; E, treated with control Fab; F, 
treated with 2 μM ADP+mFab7; G, treated with 2uM ADP+control Fab; H, treated 
with 5 μM ADP; I, molecular weight standards.  B, Quantification of actin 
incorporated into core cytoskeleton. *, p<0.05; **, p<0.01. n=3. 
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 Akt has been shown to be involved in CD9-related signaling cascades 
(Kotha 2008, Saito 2006), and its phosphorylation has been shown to be reduced 
by the tetraspanin CD151 in rat fibroblasts (Sawada 2003).  For these reasons, 
Akt phosphorylation was specifically studied. However, it did not appear that 
mFab7 ligation to CD9 altered the level of phosphorylated Akt compared to 
control Fab or saline treatments (Fig 4.16). Although it appears that Akt 
phosphorylation is not involved in mediating the platelet activation through CD9 
perturbation, it must be noted that the levels of Akt phosphosphorylation were 
very weak even in the positive controls. 
 
 Examination of Akt phosphorylation in the absence of stirring or incubation 
also showed that there was no effect induced by mFab7 ligation to CD9 (data not 
shown). 
 
 Future work may determine specific conditions under which CD9 
modulates the Akt pathway, or another signaling pathway in platelets may be 
identified as crucial to the impact of CD9 on platelet phenotypes. 
 
 
4.5.7   Tetraspanin Web Organization 
 
 Immunoprecipitations were carried out to observe the interactions 
between GPIIb-IIIa, CD9, and CD63, key members of the tetraspanin web. This 
web may be a critical scaffolding feature in the cell membrane, as well as having 
key roles in regulating GPIIb-IIIa regulation. 
 
 GPIIb-IIIa was immunoprecipitated with the antibody 10E5, which is 
capable of binding both active and inactive GPIIb-IIIa with equal affinity. It was 
capable of immunoprecipitating equivalent levels of GPIIb-IIIa when platelets 
were treated with mFab7 or control Fab, in the presence or absence of 2 μM 
ADP. An equal level of CD9 was immunoprecipitated in all samples (Fig 4.17). 
This indicates that although CD9 ligation via mFab7 may have a subtle impact on 
CD9-GPIIb-IIIa interactions, it is not capable of abolishing this interaction.  As 
previous reports indicate that the CD9-GPIIb-IIIa interaction is not dependent on 
platelet activation or integrin activation state, it is expected that mFab7 treatment 
would be capable of encouraging activation without altering the tetraspanin-
integrin association. 
 
 When platelets were treated with control Fab, CD63 was not co-
precipitated with GPIIb-IIIa, even in the presence of 2 μM ADP. This 
concentration of ADP is at the threshold of platelet activation and capable of 
inducing a low level of CD63 surface expression among a portion of the platelets.  
 
 Interestingly, mFab7 treatment increased the amount of CD63 co-
precipitated with GPIIb-IIIa. While this effect is most pronounced—as expected—
in conjunction with low-level ADP, CD63 is also co-precipitated in the absence of  
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Figure 4.16 CD9 Perturbation Does Not Appear to Alter the 
Phosphorylation of Akt 
Western blot showing level of phosphorylated Akt from platelet lysates. 
Treatments: mFab7+ADP; mFab7 without agonist; control Fab+ADP; control Fab 
without agonist; Saline control+ADP; saline control without agonist. While it 
appears that platelet activation via ADP increases Akt phosphorylation compared 
to resting samples, there is not an appreciable difference in Akt phosphorylation 
in samples treated with mFab7 versus controls. Similar results were seen in non-
stirred platelets. n=2
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Figure 4.17 CD9 Perturbation Alters Tetraspanin Web Associations 
A, GPIIb-IIIa immunoprecipitated by 10E5. B, CD63 co-immunoprecipitates with 
GPIIb-IIIa in the presence of mFab7, even in the absence of agonist stimulation, 
but does not co-immunoprecipitate with GPIIb-IIIa in the absence of mFab7, even 
in when activated by weak agonist (2 μM ADP). C, CD9 co-immunoprecipitates 
with GPIIb-IIIa equally, regardless of presence of mFab7 or ADP. 
Lanes: 1,2: mFab7; 3,4: mFab7 + 2 μM ADP; 5,6: control Fab; 7,8: control Fab + 
2 μM ADP.
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agonist. It is possible that a subset of platelets are mildly activated and thus 
expressing CD63 on the surface. It is also possible that, post-lysis, Fab7 enables 
association between CD63 from lysosomal membranes and GPIIb-IIIa/CD9 from 
the cell surface or alpha granules. Future research on the importance of CD9 in 
organization of the platelet tetraspanin web will likely yield exciting results. 
 
 
4.5.8   Clot Retraction 
 
 Surprisingly, although CD9 perturbation was shown to modulate a wide 
variety of platelet functions, treatment with mFab7 did not alter clot retraction of 
platelets in PRP (Fig 4.18). Samples treated with mFab7, control Fab, saline, and 
D3 had formed a clot by 5 minutes. Between 15 minutes and extending through 
to overnight incubation when retraction was complete, the samples treated with 
mFab7, control Fab, and saline exhibited a similar extent of platelet-mediated clot 
retraction and at a similar rate. This was true whether platelets were at 
250,000/mm3 or at 100,000/mm3. However, D3 samples were consistently 
resistant to clot retraction. 
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Figure 4.18 mFab7 Interaction with CD9 Does Not Alter Clot Retraction 
Left to right, samples are: saline; 40 μg/ml control Fab; 40 μg/ml mFab7; 80 
μg/ml D3.  A, 5 minutes after addition of CaCl2, clots are formed in all samples. 
B-F: Samples at 15 min, 30 min, 60 min, 120 min, and overnight. Samples 
treated with D3 resist clot retraction. There is no observable difference in clot 
retraction between samples treated with saline, control Fab, or mFab7. n=4. 
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CHAPTER 5   CONCLUSIONS AND RECOMMENDATIONS 
 
 
5.1   Conclusions 
 
Tetraspanins have been implicated in a wide range of cell functions. 
These include cell motility (Huang 2006), tumor cell metastasis (Takeda 2007), 
cell proliferation (Ko 2006), differentiation (Unternaehrer 2007, Saito 2006), 
sperm-egg fusion (Ziyyat 2006), and virus-induced syncytia formation (Gordon-
Elonso 2006). 
 
 
5.1.1   Localization and Protein Partners of CD9 
 
 The content of the tetraspanin web was studied under conditions of resting 
and activated platelets. As shown in Fig 4.1, the surface expression of CD9 was 
found to be quite high on platelets, and was not found to be altered when 
platelets were resting or activated with ADP or TRAP. However, there was a wide 
variability in CD9 surface expression, which could contribute to the lack of 
statistical significance. These observations suggest a role for CD9 in maintaining 
the scaffolding of the tetraspanin web or modulating the function of proteins, such 
as GPIIb-IIIa, in the tetraspanin web, and thus modulating the activation state of 
platelets, rather than having a role directly involving or requiring platelet 
activation. GPIIb-IIIa and CD151 were also found on the surface of resting 
platelets, although the surface expression of these proteins was increased upon 
platelet activation. The increase in expression is likely due to the fusion of 
granules with the surface membrane upon activation. CD63 is not expressed on 
the surface of resting platelets. It is mildly expressed under weak activation by 
ADP, and surface expression is further increased under stronger activation by 
TRAP, when platelet lysosomal membranes fuse with the platelet surface 
membrane. GPIb is found on the surface of platelets, and surface expression 
increases under ADP activation, but the surface expression is not increased 
following activation by TRAP. This may be due to the receptor becoming shed or 
endocytosed following potent activation (Bergmeier 2004).  
 
 Immunoprecipitations confirmed that CD9 and GPIIb-IIIa associate with 
each other, as each was able to co-precipitate a portion of the other (Fig 4.2). 
Eptifibatide, a small molecule which which mimics RGD-containing proteins and 
binds to GPIIb-IIIa, did not alter the level of co-precipitation, indicating that ligand 
binding does not alter the association between the integrin GPIIb-IIIa and the 
tetraspanin CD9. This further suggests a role for CD9 in regulating GPIIb-IIIa in 
both a resting and activated state.  
 
 The co-localization of CD9 and GPIIb-IIIa was also studied in spread 
platelets. A portion of the two proteins were found to be co-localized (Fig 4.3), 
consistent with immunoprecipitation data. Co-localization was observed at the 
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platelet periphery and platelet-platelet contacts, suggesting that modulation of 
GPIIb-IIIa by CD9 is most critical in forming or maintaining platelet-platelet 
interactions and in platelet spreading (Fig 4.6). Both molecules were frequently 
localized to platelet centers, as expected, since both have been reported as 
members of alpha granules (Brisson 1997). 
 
 Platelets from patients with Glanzmann Thrombasthenia, who express a 
disfunctional GPIIb-IIIa, were studied to analyze if integrin function is crucial to 
association with CD9. These platelets were still able to adhere and spread on 
fibrin and on fibrin-fibronectin, possibly through a contribution of CD9 or on other 
platelet integrins. These platelets exhibited greater spreading on fibrin, and 
decreased spreading on fibrin-fibronectin compared to normal controls (Fig 4.4). 
It is possible that these platelets exhibit an altered spreading ability, or that the 
alteration in spreading is due to an alteration in cytoskeletal linkages due to a 
mutant GPIIb-IIIa. The spreading alterations could also be due to the activation of 
different signaling cascades than normal due to activation of alternative integrins. 
Co-localization of CD9 and GPIIb-IIIa did not appear to be impacted by mutation 
of the integrin. It is interesting to note that flow cytometry confirmed a 10% 
increase in CD9 expression (data not shown), suggesting that CD9 may be partly 
compensating for the defective GPIIb-IIIa. However, it is possible that the 
increased signal could be due to better access for antibody binding to CD9. 
  
CD9 was found to localize to filopodia, lamellipodia, and platelet-platelet 
contacts in spread platelets, leading to the hypothesis that CD9 was involved in 
platelet spreading and platelet interactions, including thrombus stability (Fig 4.6 
and Fig 4.7). Interestingly, multiple studies indicate CD9 clusters at cell-cell 
contacts in a variety of cell types (Gordon-Elonso 2006, Nakamura 1995, Yang 
2006). 
 
It is interesting that CD9 was not found to localize to platelet-matrix 
contact sites on any of the matrices studied (Fig 4.5). This indicates that CD9 
may not have a direct involvement in platelet adhesion or in modulating GPIIb-
IIIa during matrix adhesion, but rather modulates GPIIb-IIIa activation during 
platelet-platelet interactions. These findings are consistent with other published 
reports, showing that tetraspanins do not localize to focal adhesions 
(Berditchevski 1999) and that modulation of integrins by tetraspanins can 
regulate adhesion strengthening but does not lead to cell adhesion to the 
extracellular matrix itself (Hemler 2001, Berditchevski 2001, Lammerding 2003). 
 
 
5.1.2   Platelet Functions Affected by CD9 Perturbation  
 
Platelet spreading has been shown to be affected by tetraspanins. CD151 
knock-out platelets exhibit impaired cell spreading on fibrinogen (Lau  2004), as 
do platelets treated with CD63-blocking antibodies (Israels 2005). Additionally, 
transfection of CD9 into Chinese Hamster Ovary (CHO cells) has been 
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previously reported to increase CHO cell spreading on collagen and fibronectin 
(Cook, 1999). We here show that CD9 is involved in platelet spreading on four 
matrices: fibrin, cross-linked fibrin-fibronectin matrix, fibronectin, and fibrinogen 
(Fig 4.9). These four matrices are all ligands for GPIIb-IIIa and are involved in 
platelet functions. Fibronectin, an extracellular matrix protein, is exposed upon 
vascular damage; fibrinogen is critical to platelet aggregation; fibrin is involved in 
clot retraction; and fibrin-fibronectin is important to wound healing. On all these 
matrices, spreading is enhanced by the presence of mFab7, an anti-CD9 Fab 
fragment, although CD9 localization is not affected. Moreover, on fibrin-
fibronectin matrix, the presence of mFab7 increases the number of platelets 
adherent to the coverslip. 
 
Platelet aggregation has been shown to be impaired in studies using 
CD151 knockout (Lau 2004) or TSSC-6 knockouts (Goschnick 2006). This, 
combined with the results that CD9 localizes to platelet-platelet contacts, led to 
the hypothesis that CD9 would be involved in thrombus stability. As shown in Fig 
4.11, when platelets were activated by threshold levels of ADP or collagen, 
preincubation with mFab7 increased thrombus formation and inhibited 
spontaneous disaggregation. This effect was not seen with the potent agonist 
TRAP, even at low levels. This could be due to the fact that TRAP seems to act 
as an ―all-or-nothing‖ signal; i.e., at increasingly lower concentrations it still 
induces a >70% aggregation, until the concentration is insufficient to elicit any 
aggregatory response. However, in the absence of agonist, mFab7 cannot evoke 
an aggregation response, even at concentrations as high as 100 μg/ml. 
Interestingly, platelet aggregations employing recombinant CD9 EC2, tagged 
with GST, show a decreased level of aggregation in response to low-dose ADP 
compared with GST-VAMP (Kotha, unpublished data). Reports also indicate that 
reduced CD9 surface expression correlate with increased platelet aggregation, 
although no causal relationship has been established yet (Vrelust 2007). It is 
possible that mFab7 treatment is inhibiting the ability of CD9 to restrain GPIIb-IIIa 
to its inactive conformation.  
 
Eptifibatide, a cyclic RGD heptapeptide which acts as a GPIIb-IIIa 
antagonist, was used to examine platelet disaggregation responses. At threshold 
levels of ADP, collagen, and TRAP, platelet aggregates were more stable over 
fifteen minutes when they were pretreated with mFab7 compared to a 
nonspecific fab control (Fig 4.12). This leads us to believe that CD9 activation or 
blockade, via mFab7 treatment, can help stabilize the active conformation of 
GPIIb-IIIa, in the presence of agonist. This effect is seen at low levels of agonist, 
whereas at higher levels, the activation of GPIIb-IIIa is so sturdy as to 
overshadow the effect of CD9. 
 
To examine the methods by which CD9 is activating GPIIb-IIIa, ligand 
binding assays were performed (Fig 4.14). mFab7, in the absence of agonist, did 
not have any effect, while in the presence of 2 M ADP, there is a significant 
increase in fibrinogen binding. This shows that CD9 does encourage GPIIb-IIIa to 
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adopt a ligand-binding-competent conformation in the presence of agonist. In Fig 
4.13, flow cytometric analysis revealed that P-selectin and CD63, markers of 
platelet activation, were increased by mFab7 pretreatment combined with ADP 
activation but not in the absence of platelet activation, revealing that in addition to 
modulating GPIIb-IIIa, CD9 perturbation also encourages platelet activation and 
release of platelet granules. 
 
It is interesting that despite being strongly involved in other platelet 
functions, CD9 perturbation did not alter clot retraction of platelets in PRP (Fig 
4.18). It is possible that the fibrin binding to GPIIb-IIIa initiating clot retraction 
leads to such a potent signal cascade, that any involvement of CD9 in clot 
retraction is overshadowed. This is particularly pertinent, as the effects of CD9 
modulation are particularly evident when platelets are mildly activated. 
 
 
5.1.3   Mechanisms Involved in Contribution of CD9 to Platelet Function 
 
As the platelet cytoskeleton plays a key role in platelet shape change, 
including filopodial and lammellipodial formation and granule release, a critical 
step in platelet spreading and aggregatory responses, any changes in 
cytoskeletal proteins induced by mFab7 were assayed. It was found, in Fig 4.15, 
that mFab7 treatment in the absence of aggregation did not impact incorporation 
of key cytoskeletal proteins compared to nonspecific control Fab. While low-dose 
(2 M) ADP induced aggregation, this aggregatory response was transient and 
insufficient to cause increased incorporation of cytoskeletal proteins in the 
absence of agonist stimulation. However, low-dose ADP combined with mFab7 
treatment resulted in increased incorporation of cytoskeletal proteins, particularly 
actin binding protein (ABP), -actinin, and actin. This increased incorporation 
was statistically greater than either ADP treatment or mFab7 treatment alone, 
and was similar to the more potent changes resulting from activation by 5 M 
ADP. 
 
Phosphorylation of signaling molecules were analyzed in an attempt to 
clarify the signaling cascade in platelets pertinent to CD9. Total tyrosine 
phosphorylation by the antibody 4G10 (not shown) indicated several proteins 
altered by platelet activation, but did not elucidate any alterations induced by 
CD9 ligation. 
 
Akt phosphorylation in particular was examined (Fig 4.16), as Akt is 
involved in CD9-related signaling cascades (Kotha 2008, Saito 2006), and 4G10 
results indicated that Akt was particularly important in platelet activation. 
However, CD9 binding did not alter the level of Akt phosphorylation in stirred or 
non-stirred platelets. Furture work may elucidate specific conditions under which 
CD9 modulates the Akt pathway. It is also possible that another signaling 
pathway in platelets may be identified as crucial to the impact of CD9 on platelet 
phenotypes. There are no known cytosolic binding partners for CD9 in human 
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platelets, but as platelets have a putative PDZ binding domain on their cytosolic 
tail, the possibility exists that an interaction will yet be defined. 
 
The importance of CD9 to the interaction of the membrane proteins GPIIb-
IIIa, CD9, and CD63 in the tetraspanin web was also studied (Fig 4.17). CD9 and 
GPIIb-IIIa association was consistent whether platelets were resting or activated, 
and was not impacted by mFab7 binding to CD9. This does not rule out the 
possibility that Fab treatment could be gently altering the association between 
CD9 and GPIIb-IIIa, but it certainly shows that it neither prohibits nor encourages 
the association. It is interesting that mFab7 treatment increased the association 
of CD63 into the tetraspanin web. This could be an indirect effect, as mFab7 
treatment increases platelet activation, and thus there is more CD63 on the 
membrane to associate in the tetraspanin web. It is possible that events resulting 
from mFab7 ligation to CD9 preferentially causes an increase in CD63 inclusion 
into the tetraspanin web, and that CD9 modulates GPIIb-IIIa via CD63. It is worth 
noting that CD9 perturbation increased CD63 association with GPIIb-IIIa even in 
the absence of agonist, and thus it is possible that mFab7 treatment causes an 
increased association in trans post-lysis. The importance of CD9 in organization 
of the platelet tetraspanin web is worthy of further research. 
  
 
5.2   Proposed Model 
 
 In the absence of CD9 perturbation via mFab7 or platelet agonist, CD9 
exists in the tetraspanin web in association with GPIIb-IIIa, which assumes a 
bent, inactivated conformation (Fig 5.1A). 
 
 The addition of mFab7, which binds to CD9 EC2, may modulate the 
association between CD9 and GPIIb-IIIa, but this impact on CD9-GPIIb-IIIa 
association is not sufficient to cause integrin activation (Fig 5.1B). mFab7 does 
not interact with the receptor FcγRII, nor does it induce signaling through this 
receptor. 
 
 In the presence of agonist, the alteration in CD9-GPIIb-IIIa interaction is 
sufficient to stabilize the extended, active conformation of GPIIb-IIIa (Fig 5.1C). 
This applies even to low, threshold levels of agonist, which would cause only a 
weak, transient activation of GPIIb-IIIa in the absence of CD9 perturbation via 
mFab7. Although mFab7 treatment does not completely abolish CD9-GPIIb-IIIa 
interactions, it is possible that the mFab7 reduces the association of CD9 EC2 
with the extracellular domains of GPIIb-IIIa, causing a phenotype associated with 
reduced CD9 expression (Vrelust 2007). It is anticipated that the impact of CD9 
perturbation would be diminished with increasing levels of agonist, as GPIIb-IIIa 
would become more strongly activated. 
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Figure 5.1 Proposed Model of CD9 Function in Platelets 
A, Resting platelet membrane. B, Binding of mFab7 does not activate GPIIb-IIIa. 
C, ADP in conjunction of mFab7 strongly activates GPIIb-IIIa. Black arrow, 
inside-out signaling from the ADP receptors P2Y1 or P2Y12 leading to activation 
and ligand binding of GPIIb-IIIa. Black circle, ligand bound to active GPIIb-IIIa.  
D, activation leads to increased linkage to the cytoskeleton and increased 
thrombus stability. 
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Figure 5.1 (continued)
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 The increase in GPIIb-IIIa activation caused by agonist in conjunction with 
CD9 alteration then leads to increased linkage of integrin to the cytoskeleton and 
increased stability of platelet agonists (Fig 5.1D). 
 
 
5.3   Recommendations for Future Study 
 
Further characterization of the mFab7-CD9 interaction will need to be 
carried out. It is unknown at this time whether mFab7 ligation is performing an 
activating or blocking role.  It is possible that mFab7 ligation is activating a signal 
cascade, which when combined with low-dose agonist, serves to encourage the 
active conformation of GPIIb-IIIa. It is also possible that mFab7 is shifting the 
conformation of CD9, leading to a direct change in the CD9-GPIIbIIIa interaction, 
whether through large extracellular loop or the fourth transmembrane domain. It 
could also be altering the association of CD9 with other tetraspanins (such as 
CD151 or CD63) or with a ligand (such as FN). It is even plausible that mFab7 is 
affecting CD9 function in trans, altering a possible extracellular interaction 
between CD9 and GPIIb-IIIa on nearby platelets. In light of other experiments 
involving CD9 function in platelets—such as the finding that platelet incubation 
with CD9 EC2 recombinant peptides inhibit platelet aggregation (J Kotha, 
unpublished data), or that decreased expression of CD9 is correlated with 
increased platelet aggregation in human patients (Vrelust 2007)—it is possible 
that CD9 encourages GPIIb-IIIa to maintain an inactive conformation, in balance 
with the tetraspanins CD151 and CD63 which seem to support activation. 
Treatment with mFab7 would then be blocking CD9 inhibition on GPIIb-IIIa, 
resulting in platelet activation in response to agonist, similarly to patients with 
reduced CD9 expression.  Further characterization will shed light on this issue. 
 
Further research using the mFab7 here created can also yield additional 
insight. It remains unclear what signaling cascades may be involved, and under 
what circumstances they may be modulated. Further characterization of the 
tetraspanin web, and the impact of CD9 modulation by mFab7, will also be 
valuable. This will provide vital information for characterizing the role of CD9 in 
modulating platelet function. More specific analysis of the exact sequence of CD9 
involved in mFab7 binding, as well as an analysis of the impact on its association 
with GPIIb-IIIa, will be insightful. Studies involving CD9 EC2 recombinant 
peptides may be a useful tool in characterizing the extracellular association 
between CD9 and GPIIb-IIIa, although the possibility that mFab7 treatment could 
also alter the transmembrane associations between CD9 and GPIIb-IIIa cannot 
be ruled out at this point. 
 
The CD9 knock-out mouse will also provide additional insight. At present, 
it is unknown what effect disruption of CD9 expression has on the expression 
levels of other tetraspanins and integrins on the platelet surface. Increased 
availability of antibodies against these murine proteins will allow expression 
levels to be quantified. Additionally, while the most obvious phenotype of these 
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mice is reduced fertility in the females (LaNaour 2000), careful studies of platelet 
function may reveal differences—which may involve increased aggregation and 
activation, rather than the inhibition seen with other tetraspanin knock-out mice. It 
is most likely that any change in platelet function will be seen using low 
concentrations of agonists. 
 
I propose that CD9 is involved in modulating the activation state of GPIIb-
IIIa. The addition of mFab7 to platelets, in the presence of ADP, reduces the CD9 
EC2 interaction with GPIIb-IIIa, allowing GPIIb-IIIa to retain an active, extended 
conformation rather than a bent, inactive conformation. It will be interesting to 
see if patients expressing reduced levels of CD9 are more at risk for thrombotic 
events; therapies targeting increased surface expression of CD9 may become 
clinically relevant in the future. 
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